

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Low-Grade Non-Hodgkin's Lymphoma

Blood

90, 2188-2195

DOI: [10.1182/blood.v90.6.2188](https://doi.org/10.1182/blood.v90.6.2188)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Non-Hodgkin's lymphoma. <i>Current Opinion in Hematology</i> , 1996, 3, 266-272.	1.2	18
3	Targeted Superantigens for Immunotherapy of Haematopoietic Tumours. <i>Vox Sanguinis</i> , 1998, 74, 483-487.	0.7	4
4	PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 1998, 22, 1159-1165.	1.3	25
5	Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. <i>Leukemia</i> , 1998, 12, 1699-1707.	3.3	45
6	The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. <i>Leukemia</i> , 1998, 12, 1971-1976.	3.3	51
7	Heat shock protein-peptide complexes as immunotherapy for human cancer. <i>Trends in Molecular Medicine</i> , 1998, 4, 478-484.	2.6	80
8	Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma. , 1998, 83, 2580-2587.		42
9	Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). <i>Annals of Hematology</i> , 1998, 77, 89-91.	0.8	85
11	Recombinant antibody fragments. <i>Current Opinion in Biotechnology</i> , 1998, 9, 395-402.	3.3	121
12	An anti-CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)-mediated cytotoxicity of a transformed human B cell line by specific CD4+ T cells. <i>Clinical and Experimental Immunology</i> , 1998, 114, 173-178.	1.1	5
13	Evaluation and management of the "New" lymphoma entities: Mantle cell lymphoma, lymphoma of mucosa-associated lymphoid tissue, anaplastic large-cell lymphoma, and primary mediastinal B-cell lymphoma. <i>Current Problems in Cancer</i> , 1998, 22, 283-368.	1.0	8
14	Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. <i>Lancet, The</i> , 1998, 352, 1285.	6.3	87
16	Tumor Immunology. <i>Immunity</i> , 1998, 9, 757-763.	6.6	140
18	Update: A Revolution in the Treatment of Non-Hodgkin's Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1998, 13, 213-223.	0.7	29
19	Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using ¹³¹ I-LYM-1 Antibody. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1998, 13, 239-254.	0.7	82
20	Rituximab: A New Therapeutic Monoclonal Antibody for Non-Hodgkin's Lymphoma. <i>Cancer Practice</i> , 1998, 6, 195-197.	0.8	100
21	New drugs in the treatment of Hodgkin's disease. <i>Annals of Oncology</i> , 1998, 9, s103-s108.	0.6	18
22	New Therapeutic Monoclonal Antibodies Target Kidney Transplant Rejection and Cancer. <i>Journal of the American Pharmacists Association</i> , 1998, 38, 379-380.	0.6	3

#	ARTICLE	IF	CITATIONS
23	Multicentric Osteosarcoma, Rothmund-Thomson Syndrome, and Secondary Nasopharyngeal Non-Hodgkin's Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 1998, 20, 494-497.	0.3	28
24	Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2825-2833.	0.8	2,616
25	Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1998, 9, 995-1001.	0.6	479
26	Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8,) Tj ETQq1 1 0.784314 rgBT /Overloc 0.6 144	0.6	144
27	Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 1998, 16, 3916-3917.	0.8	32
28	Concurrent G-CSF and chemotherapy.. <i>Journal of Clinical Oncology</i> , 1998, 16, 3917-3917.	0.8	1
29	Glutamine treatment of paclitaxel-induced myalgias and arthralgias.. <i>Journal of Clinical Oncology</i> , 1998, 16, 3918-3919.	0.8	44
30	Monoclonal antibody-based therapies for hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 1998, 16, 3691-3710.	0.8	71
31	Monoclonal Antibodies in the Treatment of Human B-Cell Malignancies. <i>Leukemia and Lymphoma</i> , 1998, 31, 237-249.	0.6	14
32	Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity. <i>Annals of Oncology</i> , 1999, 10, 1525-1527.	0.6	93
33	Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance. <i>Journal of Clinical Oncology</i> , 1999, 17, 791-791.	0.8	250
34	Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20 ⁺ B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3793-3803.	0.8	525
35	Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab. <i>Journal of Clinical Oncology</i> , 1999, 17, 1851-1851.	0.8	274
36	Clinical Investigation of the Monoclonal Anti-CD20 Antibody Rituximab (IDEC-C2B8) in Patients with B Cell Lymphoma. <i>Contributions To Oncology / Beitrage Zur Onkologie</i> , 1999, 54, 343-360.	0.1	0
37	The Importance of Antibody-Specificity in Determining Successful Radioimmunotherapy of B-Cell Lymphoma. <i>Blood</i> , 1999, 94, 233-243.	0.6	27
38	Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8). <i>Blood</i> , 1999, 94, 2217-2224.	0.6	608
39	Pharmacology and Safety Assessment of Humanized Monoclonal Antibodies for Therapeutic Use. <i>Toxicologic Pathology</i> , 1999, 27, 1-3.	0.9	35
40	Multiple myeloma: An update on biology and treatment. <i>Annals of Oncology</i> , 1999, 10, S31-S43.	0.6	8

#	ARTICLE	IF	CITATIONS
41	Cancer dormancy and cell signaling: Induction of p21waf1 initiated by membrane IgM engagement increases survival of B lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8711-8715.	3.3	42
42	STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14523-14528.	3.3	294
43	Progress in the non-Hodgkin's lymphomas. Annals of Oncology, 1999, 10, S19-S22.	0.6	1
44	Rituximab (Anti-CD20 Monoclonal Antibody) Administration in a Young Patient with Resistant B-Prolymphocytic Leukemia. Acta Haematologica, 1999, 102, 94-98.	0.7	18
45	Pretargeting with the Affinity Enhancement System for Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 1999, 14, 153-166.	0.7	65
46	Autologous Bone Marrow Transplants to Hematopoietic Stem Cell Support with Peripheral Blood Stem Cells: A Historical Perspective. Stem Cells and Development, 1999, 8, 233-236.	1.0	20
47	Rituximab Immunotherapy for Non-Hodgkin's Lymphoma. Cancer Biotherapy and Radiopharmaceuticals, 1999, 14, 241-250.	0.7	13
48	Signaling antibodies in cancer therapy. Current Opinion in Immunology, 1999, 11, 541-547.	2.4	125
49	Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Trends in Immunology, 1999, 20, 576-582.	7.5	194
50	Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.. British Journal of Haematology, 1999, 106, 47-54.	1.2	49
51	Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. British Journal of Haematology, 1999, 106, 545-552.	1.2	28
52	CLONAL SELECTION OF CD20-NEGATIVE NON-HODGKIN'S LYMPHOMA CELLS AFTER TREATMENT WITH ANTI-CD20 ANTIBODY RITUXIMAB. British Journal of Haematology, 1999, 106, 571-572.	1.2	43
53	Improving antibody affinity by mimicking somatic hypermutation in vitro. Nature Biotechnology, 1999, 17, 568-572.	9.4	238
54	Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplantation, 1999, 24, 1253-1258.	1.3	43
55	Molecular markers of B-cell lymphoma. Seminars in Cancer Biology, 1999, 9, 139-147.	4.3	8
56	Toxicology and Pharmacokinetics of DTGM, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT388) Linked to Human Granulocyte-Macrophage Colony-Stimulating Factor, in Cynomolgus Monkeys. Toxicology and Applied Pharmacology, 1999, 158, 152-160.	1.3	29
57	Detection and relevance of minimal disease in lymphomas. , 1999, 18, 127-142.		15
58	Engeladener Kommentar zu: "Radioimmuntherapie" Ergebnisse und Entwicklungsmöglichkeiten. Acta Chirurgica Austriaca, 1999, 31, 30-30.	0.2	1

#	ARTICLE	IF	CITATIONS
59	Current status and perspectives in cancer chemotherapy. <i>Breast Cancer</i> , 1999, 6, 270-274.	1.3	1
60	Behandlung von malignen Lymphomen mit dem mono-klonalen anti-CD20 Antikörper Rituximab (IDEC-C2B8). <i>Onkologe</i> , 1999, 5, 532-540.	0.7	1
61	T cell-based immunotherapy for cancer: a virtual reality?. <i>Ca-A Cancer Journal for Clinicians</i> , 1999, 49, 74-100.	157.7	11
62	Taking engineered anti-CEA antibodies to the clinic. <i>Journal of Immunological Methods</i> , 1999, 231, 261-273.	0.6	34
63	Clinical applications of anti-CD20 antibodies. <i>Translational Research</i> , 1999, 134, 445-450.	2.4	95
64	Non-Hodgkin's Lymphoma in the Elderly. <i>Drugs and Aging</i> , 1999, 14, 447-457.	1.3	6
65	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN NON-HODGKIN'S LYMPHOMA. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 889-918.	0.9	11
66	Monoclonal Antibodies in Cancer Treatment. <i>BioDrugs</i> , 1999, 12, 209-236.	2.2	6
68	New Chemoimmunotherapy: Courtesy of a More Flexible Food and Drug Administration. <i>Cancer Investigation</i> , 1999, 17, 371-373.	0.6	0
69	Low-Grade Lymphomas. <i>Cancer Investigation</i> , 1999, 17, 93-93.	0.6	1
70	Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy. <i>European Journal of Cancer</i> , 1999, 35, 549-557.	1.3	13
71	GM-CSF as adjuvant for immunotherapy with bispecific antibodies. <i>European Journal of Cancer</i> , 1999, 35, S25-S28.	1.3	2
73	Radionuclide therapy. <i>Lancet, The</i> , 1999, 354, 931-935.	6.3	83
74	Rituximab. <i>Drugs</i> , 1999, 58, 79-88.	4.9	121
75	Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 1999, 12, 151-169.	0.7	14
76	Principles of diagnosis, staging and management. <i>Imaging</i> , 1999, 11, 214-229.	0.0	0
77	Antibody Therapy with Rituximab for Patients with Low-Grade Non-Hodgkin's Lymphoma. <i>Oncology Research and Treatment</i> , 1999, 22, 184-190.	0.8	0
78	Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1999, 10, 655-661.	0.6	329

#	ARTICLE	IF	CITATIONS
79	Lymphoid Aggregates in Bone Marrow Mimic Residual Lymphoma After Rituximab Therapy for Non-Hodgkin Lymphoma. <i>American Journal of Clinical Pathology</i> , 1999, 112, 844-853.	0.4	40
80	Antibody therapy has arrived. Now where does it fit?. <i>Annals of Oncology</i> , 1999, 10, 619-621.	0.6	7
81	Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy. <i>Journal of Clinical Oncology</i> , 1999, 17, 268-268.	0.8	850
82	Bendamustine in the Treatment of Low-Grade Non-Hodgkin's Lymphomas. <i>Oncology Research and Treatment</i> , 2000, 23, 318-324.	0.8	7
83	Chronic lymphocytic leukemia. <i>Current Opinion in Hematology</i> , 2000, 7, 223-234.	1.2	86
84	Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma. <i>Journal of Immunotherapy</i> , 2000, 23, 473-479.	1.2	60
85	Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells. <i>Biotechnology and Bioengineering</i> , 2000, 67, 97-103.	1.7	53
86	Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. <i>Cancer</i> , 2000, 89, 1835-1844.	2.0	126
87	Sustained Systemic Delivery of Monoclonal Antibodies by Genetically Modified Skin Fibroblasts. <i>Journal of Investigative Dermatology</i> , 2000, 115, 740-745.	0.3	14
88	Rituximab in cutaneous B-cell lymphoma: a report of two cases. <i>British Journal of Dermatology</i> , 2000, 143, 157-161.	1.4	50
89	The Emerging Role Of Radioimmunotherapy In Haematological Malignancies. <i>British Journal of Haematology</i> , 2000, 108, 679-688.	1.2	29
90	A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. <i>British Journal of Haematology</i> , 2000, 109, 81-88.	1.2	101
91	In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2000, 109, 729-735.	1.2	80
92	Rituximab salvage following relapse after allogeneic bone marrow transplantation for non-hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2000, 110, 1013-1014.	1.2	4
93	Rituximab salvage following relapse after allogeneic bone marrow transplantation for non-hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2000, 110, 1013-1014.	1.2	2
94	Rituximab (Anti-CD20) Therapy of B-Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms. <i>Scandinavian Journal of Immunology</i> , 2000, 51, 634-641.	1.3	234
95	Follicular lymphomas â€” a review of treatment modalities. <i>Critical Reviews in Oncology/Hematology</i> , 2000, 35, 13-32.	2.0	15
96	Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival. <i>Bone Marrow Transplantation</i> , 2000, 26, 1051-1056.	1.3	13

#	ARTICLE	IF	CITATIONS
97	Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. <i>Leukemia</i> , 2000, 14, 740-747.	3.3	35
98	Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2000, 24, 411-415.	0.4	76
99	Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. <i>Cancer Immunology, Immunotherapy</i> , 2000, 48, 673-683.	2.0	380
100	IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. <i>Annals of Hematology</i> , 2000, 79, 493-500.	0.8	96
101	Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2000, 79, 167-174.	0.8	13
102	Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. <i>Annals of Hematology</i> , 2000, 79, 175-182.	0.8	60
103	Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab. <i>Annals of Hematology</i> , 2000, 79, 332-335.	0.8	16
104	Immunostimulatory DNA sequences and cancer therapy. <i>Seminars in Immunopathology</i> , 2000, 22, 107-116.	4.0	14
105	Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. <i>Medical Oncology</i> , 2000, 17, 203-210.	1.2	27
106	Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. <i>Blood</i> , 2000, 95, 3052-3056.	0.6	271
107	CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. <i>Blood</i> , 2000, 95, 1502-1505.	0.6	262
108	Therapeutic efficacy of Fc γ RI/CD64-directed bispecific antibodies in B-cell lymphoma. <i>Blood</i> , 2000, 96, 3544-3552.	0.6	61
109	Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. <i>Blood</i> , 2000, 96, 4055-4063.	0.6	167
110	Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Re-Treatment. <i>Journal of Clinical Oncology</i> , 2000, 18, 3135-3143.	0.8	653
111	Primary Cutaneous B-Cell Lymphoma: Review and Current Concepts. <i>Journal of Clinical Oncology</i> , 2000, 18, 2152-2168.	0.8	105
112	High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up. <i>Journal of Clinical Oncology</i> , 2000, 18, 527-527.	0.8	168
113	European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 317-317.	0.8	448
114	Treatment advances in non-Hodgkin's lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 451-465.	0.9	4

#	ARTICLE	IF	CITATIONS
115	Salvage Therapy for Relapsed Mediastinal B-Cell Lymphoma with Allogeneic HLA-Identical Related Donor Bone Marrow Transplantation, Donor Lymphocyte Infusion and IDEC-C2B8. <i>Leukemia and Lymphoma</i> , 2000, 40, 133-140.	0.6	7
116	Intralesional Therapy With Anti-CD20 Monoclonal Antibody Rituximab in Primary Cutaneous B-Cell Lymphoma. <i>Archives of Dermatology</i> , 2000, 136, 374-8.	1.7	84
117	Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response. <i>Annals of Oncology</i> , 2000, 11, S117-S121.	0.6	59
118	The effect of Rituximab on patients with follicular and mantle-cell lymphoma. <i>Annals of Oncology</i> , 2000, 11, S123-S126.	0.6	62
119	Acute Toxicity of Mitoxantrone, Chlorambucil and Prednisolone (MCP) versus MCP plus Rituximab in Low-Grade Non-Hodgkin's Lymphoma – Interim Results of a Phase III Trial. <i>Oncology Research and Treatment</i> , 2000, 23, 164-166.	0.8	1
120	The Application of Monoclonal Antibodies in the Treatment of Lymphoma. <i>Methods in Molecular Medicine</i> , 2000, 40, 85-97.	0.8	2
121	Radioimmunotherapy in the BCL1B cell Lymphoma Model: Efficacy Depends on More Than Targeted Irradiation Alone. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2000, 15, 581-591.	0.7	10
122	Demystified ...: Monoclonal antibodies. <i>Journal of Clinical Pathology</i> , 2000, 53, 111-117.	2.1	160
123	Monoclonal Antibody Therapy in Lymphoid Malignancies. <i>Oncologist</i> , 2000, 5, 376-384.	1.9	56
124	Effect of interferon- γ on CD20 antigen expression of B-cell chronic lymphocytic leukemia. <i>Cytokines, Cellular & Molecular Therapy</i> , 2000, 6, 81-87.	0.3	36
126	Monoclonal antibody therapy for solid tumors. <i>Cancer Treatment Reviews</i> , 2000, 26, 269-286.	3.4	142
127	Cutaneous lymphomas. <i>Current Problems in Dermatology</i> , 2000, 12, 25-29.	0.1	0
128	Anti-CD20 monoclonal antibody therapy in Epstein-Barr virus-associated B cell lymphoma following lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 492-495.	0.3	17
129	Monoclonal antibodies in lymphoid neoplasia: Principles for optimal combined therapy. <i>Seminars in Hematology</i> , 2000, 37, 17-26.	1.8	13
130	Monoclonal antibody-based therapy of lymphoid neoplasms: What's on the horizon?. <i>Seminars in Hematology</i> , 2000, 37, 34-42.	1.8	2
131	The Role of Natural Products in Drug Discovery. , 2000, , .		3
132	Management of Chronic Lymphocytic Leukaemia. <i>Drugs and Aging</i> , 2000, 16, 9-27.	1.3	40
133	Emerging concepts in the management of the malignant haematological disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 713-735.	0.9	4

#	ARTICLE	IF	CITATIONS
134	Anti-Interleukin-12 Antibody. <i>BioDrugs</i> , 2000, 13, 233-241.	2.2	2
135	Immunotherapy of a Viral Disease by in Vivo Production of Therapeutic Monoclonal Antibodies. <i>Human Gene Therapy</i> , 2000, 11, 1407-1415.	1.4	30
136	Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity. <i>Hybridoma</i> , 2000, 19, 463-471.	0.9	37
137	Infection and Immunity in Chronic Lymphocytic Leukemia. <i>Mayo Clinic Proceedings</i> , 2000, 75, 1039-1054.	1.4	124
138	State of the art of therapy in nuclear medicine. <i>Revista Española De Medicina Nuclear</i> , 2000, 19, 437-451.	0.3	2
140	Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, 146-151.	2.1	11
141	Rituximab Therapy of B-Cell Neoplasms. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, 186-194.	2.1	25
142	Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. <i>Journal of Hepatology</i> , 2000, 32, 521-527.	1.8	60
143	Strategies for immunotherapy of cancer. <i>Advances in Immunology</i> , 2000, 75, 235-282.	1.1	138
144	Achieving Optimal Outcomes in Chronic Lymphocytic Leukaemia. <i>Drugs</i> , 2001, 61, 593-611.	4.9	16
145	Phase II Trial of Remigeon (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 188-190.	2.1	26
146	ANTIBODY-DIRECTED, EFFECTOR CELL-MEDIATED TUMOR DESTRUCTION. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 703-721.	0.9	38
147	Hapten-Induced Primary and Memory Humoral Responses Are Inhibited by the Infusion of Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab). <i>Clinical Immunology</i> , 2001, 98, 175-179.	1.4	67
148	How immunology is reshaping clinical disciplines: the example of haematology. <i>Lancet</i> , 2001, 358, 49-55.	6.3	14
149	BIOLOGIC RESPONSE MODIFIERS IN PEDRIATIC CANCER. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 723-740.	0.9	12
150	Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. <i>Blood</i> , 2001, 97, 3995-3997.	0.6	147
151	Radioimmunotherapy. <i>BioDrugs</i> , 2001, 15, 151-162.	2.2	11
152	Rituximab for Bone Lymphoma. <i>Annals of Internal Medicine</i> , 2001, 134, 1156.	2.0	4

#	ARTICLE	IF	CITATIONS
153	Ethical Principles for Everyone. <i>Annals of Internal Medicine</i> , 2001, 134, 1151.	2.0	0
154	Blinding in Placebo-Controlled Trials. <i>Annals of Internal Medicine</i> , 2001, 134, 1150.	2.0	1
155	Blinding in Placebo-Controlled Trials. <i>Annals of Internal Medicine</i> , 2001, 134, 1150.	2.0	0
156	Treatment of Lipodystrophy with Troglitazone. <i>Annals of Internal Medicine</i> , 2001, 134, 1153.	2.0	0
157	Rituximab: An innovative therapy for non-Hodgkin's lymphoma. <i>American Journal of Health-System Pharmacy</i> , 2001, 58, 215-229.	0.5	19
158	Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity. <i>Journal of Clinical Oncology</i> , 2001, 19, 2153-2164.	0.8	487
159	Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. <i>Anti-Cancer Drugs</i> , 2001, 12, 725-729.	0.7	94
160	Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. <i>Journal of Immunotherapy</i> , 2001, 24, 263-271.	1.2	188
161	Primary Cutaneous Large B-Cell Lymphoma of the Legs. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 237-240.	0.6	35
163	Transformation of Hodgkin's disease to high-grade B-cell lymphoma: Remission after Rituximab monotherapy. <i>Annals of Oncology</i> , 2001, 12, 1169-1171.	0.6	5
164	Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. <i>Annals of Oncology</i> , 2001, 12, 109-114.	0.6	58
165	Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen A2 binding residues. <i>Blood</i> , 2001, 98, 2999-3005.	0.6	57
166	Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. <i>Blood</i> , 2001, 98, 952-957.	0.6	531
167	Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 389-397.	0.8	415
168	The Efficacy of Spiritual Healing. <i>Annals of Internal Medicine</i> , 2001, 134, 1150.	2.0	1
169	Tamoxifen-Induced Total Alopecia. <i>Annals of Internal Medicine</i> , 2001, 134, 1154.	2.0	22
170	Immunotherapy of Non-Hodgkin's Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2001, 2001, 221-240.	0.9	72
171	Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1725-1735.	2.2	27

#	ARTICLE	IF	CITATIONS
172	Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. <i>Annals of Hematology</i> , 2001, 80, 170-173.	0.8	36
173	Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab. <i>Annals of Hematology</i> , 2001, 80, 479-481.	0.8	10
174	Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. <i>Annals of Hematology</i> , 2001, 80, 549-552.	0.8	68
176	Naive and memory B cells in T-cell-dependent and T-independent responses. <i>Seminars in Immunopathology</i> , 2001, 23, 405-419.	4.0	54
177	Pathologie, Biologie und Klassifikation maligner Non-Hodgkin-Lymphome. <i>Onkologe</i> , 2001, 7, 940-959.	0.7	5
178	Neue Standards in der Therapie aggressiver Lymphome. <i>Onkologe</i> , 2001, 7, 998-1013.	0.7	2
179	Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab. <i>International Journal of Hematology</i> , 2001, 73, 213-221.	0.7	43
180	Assessment of Prognostic Factors in Follicular Lymphoma Patients. <i>International Journal of Hematology</i> , 2001, 73, 363-368.	0.7	19
181	Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody. <i>International Journal of Hematology</i> , 2001, 74, 70-75.	0.7	39
182	Intralesional rituximab for cutaneous B-cell lymphoma. <i>British Journal of Dermatology</i> , 2001, 144, 1239-1243.	1.4	71
183	Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. <i>British Journal of Haematology</i> , 2001, 115, 112-118.	1.2	125
184	Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. <i>British Journal of Haematology</i> , 2001, 115, 79-83.	1.2	100
185	Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 37, 13-25.	2.0	37
186	Rituximab: perspective on single agent experience, and future directions in combination trials. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 40, 3-16.	2.0	72
187	Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC γ RIII. <i>Biotechnology and Bioengineering</i> , 2001, 74, 288-294.	1.7	301
188	Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. <i>American Journal of Hematology</i> , 2001, 68, 292-294.	2.0	61
189	Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). <i>Arthritis and Rheumatism</i> , 2001, 44, 1717-1718.	6.7	96
190	Rituximab (Mabthera TM , Rituxan TM) in Patients with Recurrent Indolent Lymphoma. <i>Medical Oncology</i> , 2001, 18, 141-148.	1.2	24

#	ARTICLE	IF	CITATIONS
191	Antibodies in the Treatment of Lymphoma. <i>Clinical Oncology</i> , 2001, 13, 251-261.	0.6	1
192	Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. <i>Cancer Gene Therapy</i> , 2001, 8, 378-387.	2.2	31
193	Remission of severe cold agglutinin disease Rituximab therapy. <i>Leukemia</i> , 2001, 15, 187-188.	3.3	45
194	Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion. <i>Leukemia</i> , 2001, 15, 186-187.	3.3	21
195	Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma. <i>Leukemia</i> , 2001, 15, 832-839.	3.3	15
196	CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. <i>Leukemia</i> , 2001, 15, 1619-1626.	3.3	124
197	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. <i>Leukemia</i> , 2001, 15, 1941-1949.	3.3	49
198	Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics. <i>Journal of Immunological Methods</i> , 2001, 248, 31-45.	0.6	90
199	Pharmacokineticâ€“pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. <i>Journal of Immunological Methods</i> , 2001, 248, 149-165.	0.6	28
200	Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab. <i>Experimental Hematology</i> , 2001, 29, 1410-1416.	0.2	33
201	Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopeniaâ€“and neutropenia. <i>European Journal of Haematology</i> , 2001, 66, 408-411.	1.1	41
202	When Cancer and Heart Failure Cross Paths: A Case Report of Severe Cardiorenal Compromise Associated with the Anti-CD20 Monoclonal Antibody Rituximab in a Patient with Dilated Cardiomyopathy. <i>Congestive Heart Failure</i> , 2001, 7, 223-227.	2.0	6
203	Diagnosis and Management of Posttransplant Lymphoproliferative Disorder in Solidâ€“Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2001, 33, S38-S46.	2.9	106
204	Monoclonal Antibody Therapy in the Treatment of Non-Hodgkin Lymphoma. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 1149.	3.8	18
205	Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. <i>Protein Engineering, Design and Selection</i> , 2001, 14, 1025-1033.	1.0	47
206	Specific Immunotherapy for Non-Hodgkin's Lymphoma. <i>Laboratory Medicine</i> , 2001, 32, 609-616.	0.8	0
207	Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma. <i>International Journal of Oncology</i> , 2001, 19, 897-902.	1.4	5
208	Evaluation on a Six-Dose Treatment of Anti CD 20 Monoclonal Antibody in Patients with Refractory Follicular Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2001, 16, 159-162.	0.7	5

#	ARTICLE	IF	CITATIONS
209	Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis. <i>Leukemia and Lymphoma</i> , 2001, 42, 1329-1337.	0.6	28
210	Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. <i>Blood</i> , 2001, 97, 101-106.	0.6	506
211	A Systematic Overview of Chemotherapy Effects in Indolent Non-Hodgkin's Lymphoma. <i>Acta Oncologica</i> , 2001, 40, 213-223.	0.8	32
212	Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 42, 731-738.	0.6	93
213	A Magic Bullet for Cancer â€” How Near and How Far?. <i>New England Journal of Medicine</i> , 2001, 345, 283-284.	13.9	7
214	Antibody therapy of lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 953-961.	0.9	13
215	Vaccine Therapy of B Cell Malignancies: Different Strategies for a Novel Approach. <i>Leukemia and Lymphoma</i> , 2001, 42, 881-889.	0.6	3
216	Rituximab in the Treatment of Refractory Follicular Lymphoma - Six Doses Are Better Than Four. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 313-316.	1.8	11
217	Monoclonal antibody therapy. <i>Advances in Protein Chemistry</i> , 2001, 56, 369-421.	4.4	11
218	Tyrosine Kinase Inhibitors Suppress the Growth of Non-Hodgkin B Lymphomas. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 303, 163-171.	1.3	4
219	High In Vivo Production of a Model Monoclonal Antibody on Adenoviral Gene Transfer. <i>Human Gene Therapy</i> , 2002, 13, 1483-1493.	1.4	34
220	Treating human autoimmune disease by depleting B cells. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 863-866.	0.5	66
221	Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. <i>Annals of Oncology</i> , 2002, 13, 928-943.	0.6	127
222	Current strategies of antibody-based treatment in Hodgkin's disease. <i>Annals of Oncology</i> , 2002, 13, 57-66.	0.6	24
223	Randomized Phase III Study of Fludarabine Phosphate Versus Cyclophosphamide, Vincristine, and Prednisone in Patients With Recurrent Low-Grade Non-Hodgkin's Lymphoma Previously Treated With an Alkylating Agent or Alkylator-Containing Regimen. <i>Journal of Clinical Oncology</i> , 2002, 20, 4649-4654.	0.8	62
224	Randomized Controlled Trial of Yttrium-90 Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2453-2463.	0.8	1,069
225	The Complete Spleen. , 2002, , .		35
226	Immune-based therapies: A review of clinical endpoints used in trials of selected immunologic agents, by the Forum for Collaborative HIV Research. <i>HIV Clinical Trials</i> , 2002, 3, 58-88.	2.0	2

#	ARTICLE	IF	CITATIONS
227	CHOP plus Rituximab â€” Balancing Facts and Opinion. <i>New England Journal of Medicine</i> , 2002, 346, 280-282.	13.9	45
228	Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. <i>Bone Marrow Transplantation</i> , 2002, 29, 769-775.	1.3	44
229	Rituximab: clinical development and future directions. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 97-110.	1.4	36
231	Application of Recombinant Antibodies in Cancer Patients. , 2003, 207, 27-54.		0
232	Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 922-924.	0.5	121
233	Advances in the treatment of non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2002, 13, 211-216.	0.6	9
234	Stevensâ€™Johnson syndrome after treatment with rituximab. <i>Annals of Oncology</i> , 2002, 13, 1948-1950.	0.6	96
235	Progress and Promise in the Treatment of Indolent Lymphomas. <i>Oncologist</i> , 2002, 7, 217-225.	1.9	23
236	Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkinâ€™s Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 4261-4267.	0.8	388
238	CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2002, 20, 1278-1287.	0.8	59
240	Rituximab for Aggressive Non-Hodgkin??s Lymphomas Relapsing After or Refractory to Autologous Stem Cell Transplantation. <i>Cancer Journal (Sudbury, Mass)</i> , 2002, 8, 371-376.	1.0	23
241	Strategy for the treatment of acute myelogenous leukemia based on folate receptor Î²â€™targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. <i>Blood</i> , 2002, 100, 594-602.	0.6	185
242	Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2002, 99, 67-74.	0.6	149
243	The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. <i>Blood</i> , 2002, 99, 1038-1043.	0.6	350
244	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. <i>Blood</i> , 2002, 99, 856-862.	0.6	155
245	Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcÎ³R11a gene. <i>Blood</i> , 2002, 99, 754-758.	0.6	1,819
246	Reovirus therapy of lymphoid malignancies. <i>Blood</i> , 2002, 100, 4146-4153.	0.6	100
247	Cancer Vaccines for Hematologic Malignancies. <i>Cancer Control</i> , 2002, 9, 138-151.	0.7	23

#	ARTICLE	IF	CITATIONS
248	Treatment of Epstein-Barr virus-associated malignancies with specific T cells. <i>Advances in Cancer Research</i> , 2002, 84, 175-201.	1.9	53
249	Treatment of Waldenström's Macroglobulinemia With Rituximab. <i>Journal of Clinical Oncology</i> , 2002, 20, 2327-2333.	0.8	248
250	CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 235-242.	13.9	4,928
251	Antibody-based therapy of non-Hodgkin's lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 449-465.	0.7	10
252	Mitoxantrone/Ifosfamide/Etoposide Salvage Regimen with Rituximab for In Vivo Purging in Patients with Relapsed Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 111-116.	2.1	8
253	Extended Rituximab Therapy for Previously Untreated Patients with Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 163-166.	2.1	71
254	Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 544-549.	2.0	12
255	Recurrent B-cell Neoplasms After Rituximab Therapy: An Immunophenotypic and Genotypic Study. <i>Leukemia and Lymphoma</i> , 2002, 43, 2335-2341.	0.6	40
256	Monoclonal Antibody Therapy of Haematological Malignancies. <i>BioDrugs</i> , 2002, 16, 283-301.	2.2	10
257	Pharmacotherapy of primary CNS lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 39-49.	0.9	6
258	Rituximab and other emerging monoclonal antibody therapies for lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2002, 7, 289-302.	1.0	10
260	Monotherapy with the anti-cd20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease. <i>Transplantation Proceedings</i> , 2002, 34, 1178-1181.	0.3	16
261	CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. <i>Journal of the American Academy of Dermatology</i> , 2002, 46, 441-443.	0.6	28
262	Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 623-628.	0.6	37
263	Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2002, 21, 1304-1309.	0.3	21
264	Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 2260-2262.	0.6	83
265	Rituximab in Combination with Chop Improves Survival in Elderly Patients with Aggressive Non-Hodgkin's Lymphoma. <i>Tumori</i> , 2002, 88, S26-S28.	0.6	7
266	Antibodies to Heterologous Proteins in Hemophilia A Patients Receiving Recombinant Factor VIII (Recombinate®, [®]). <i>Thrombosis and Haemostasis</i> , 2002, 87, 626-634.	1.8	14

#	ARTICLE	IF	CITATIONS
267	CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2002, 20, 1278-1287.	0.8	79
268	Advances in classification and therapy of indolent B-cell malignancies. <i>Seminars in Oncology</i> , 2002, 29, 98-104.	0.8	21
269	Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. <i>Seminars in Oncology</i> , 2002, 29, 87-92.	0.8	56
270	Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal) Tj ETQq1 1 0.784314 rgBT /Overloc	0.8	64
271	Rituximab in the treatment of diffuse large B-cell lymphomas. <i>Seminars in Oncology</i> , 2002, 29, 30-35.	0.8	51
272	Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial. <i>Seminars in Oncology</i> , 2002, 29, 25-29.	0.8	36
273	Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. <i>Seminars in Oncology</i> , 2002, 29, 10-24.	0.8	37
274	Rituximab: Mechanism of action and resistance. <i>Seminars in Oncology</i> , 2002, 29, 2-9.	0.8	297
275	Immunochemotherapy in indolent non-Hodgkin's lymphoma. <i>Seminars in Oncology</i> , 2002, 29, 11-17.	0.8	26
276	Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. <i>Seminars in Oncology</i> , 2002, 29, 18-22.	0.8	94
277	Hematologic malignancies: New developments and future treatments. <i>Seminars in Oncology</i> , 2002, 29, 33-45.	0.8	4
278	Focus on lymphomas. <i>Cancer Cell</i> , 2002, 2, 363-366.	7.7	21
279	Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. <i>European Journal of Haematology</i> , 2002, 69, 21-26.	1.1	26
280	Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. <i>European Journal of Haematology</i> , 2002, 69, 95-100.	1.1	113
281	Treatment of a patient with end-stage renal disease with Rituximab: Pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. <i>American Journal of Hematology</i> , 2002, 71, 219-222.	2.0	62
282	Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells. <i>Arthritis and Rheumatism</i> , 2002, 46, 2029-2033.	6.7	240
283	Monoclonal Antibody Therapy for B-Cell Lymphoma. <i>International Journal of Hematology</i> , 2002, 76, 385-393.	0.7	34
284	Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan. <i>International Journal of Hematology</i> , 2002, 76, 411-419.	0.7	23

#	ARTICLE	IF	CITATIONS
285	Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. <i>Annals of Hematology</i> , 2002, 81, 26-32.	0.8	76
286	Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial - Intergroup Collaborative Study. <i>Annals of Hematology</i> , 2002, 81, 553-557.	0.8	11
287	Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2002, 128, 161-166.	1.2	33
288	Analysis of the B-cell repertoire against antigens expressed by human neoplasms. <i>Immunological Reviews</i> , 2002, 188, 43-50.	2.8	102
289	Skin as a Potential Organ for Ectopic Monoclonal Antibody Production11The authors declared not to have a conflict of interest.. <i>Journal of Investigative Dermatology</i> , 2002, 118, 288-294.	0.3	11
290	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2002, 117, 828-834.	1.2	131
291	Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma*. <i>British Journal of Haematology</i> , 2002, 119, 125-127.	1.2	58
292	Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. <i>British Journal of Haematology</i> , 2002, 119, 412-416.	1.2	108
293	Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study. <i>Bone Marrow Transplantation</i> , 2002, 30, 229-234.	1.3	15
294	Anti-CD20-based therapy of B cell lymphoma: state of the art. <i>Leukemia</i> , 2002, 16, 2004-2015.	3.3	58
295	Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon- β . <i>Leukemia Research</i> , 2002, 26, 745-755.	0.4	13
296	Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic Malignancies. <i>Stem Cells</i> , 2002, 20, 215-229.	1.4	49
297	Biodistribution and kinetics of ^{131}I -labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1276-1282.	3.3	42
298	The IL-2/IL-15 receptor systems: targets for immunotherapy. <i>Journal of Clinical Immunology</i> , 2002, 22, 51-56.	2.0	85
299	Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?. <i>Journal of Clinical Immunology</i> , 2002, 22, 124-130.	2.0	64
300	Recombinant Antibodies for the Diagnosis and Treatment of Cancer. <i>Molecular Biotechnology</i> , 2003, 25, 1-18.	1.3	12
301	BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models. <i>Journal of Neuro-Oncology</i> , 2003, 65, 49-62.	1.4	40
302	Rituximab Treatment for Relapsed Autoimmune Hemolytic Anemia in Evans Syndrome. <i>International Journal of Hematology</i> , 2003, 78, 335-336.	0.7	17

#	ARTICLE	IF	CITATIONS
303	Cellular and molecular themes in apoptosis. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 563-574.	1.0	8
304	Innovative strategies in lymphoma therapy. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 462-470.	1.0	2
305	CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. <i>Annals of Hematology</i> , 2003, 82, 585-588.	0.8	39
306	Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 90-96.	1.1	1
307	Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma. <i>International Journal of Clinical Oncology</i> , 2003, 8, 212-223.	1.0	12
308	Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab. <i>Seminars in Cancer Biology</i> , 2003, 13, 223-231.	4.3	13
309	Immunotherapy with anti-CD20 compounds. <i>Seminars in Cancer Biology</i> , 2003, 13, 211-222.	4.3	17
310	Loss of CD20 expression in relapsed lymphomas after rituximab therapy. <i>European Journal of Haematology</i> , 2003, 70, 330-332.	1.1	51
311	History of antibody therapy for non-Hodgkin's lymphoma. <i>Seminars in Oncology</i> , 2003, 30, 1-5.	0.8	38
312	Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. <i>Seminars in Oncology</i> , 2003, 30, 434-447.	0.8	32
313	Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. <i>Seminars in Oncology</i> , 2003, 30, 476-482.	0.8	28
314	CD22-directed monoclonal antibody therapy for lymphoma. <i>Seminars in Oncology</i> , 2003, 30, 457-464.	0.8	27
315	Radioimmunotherapy for non-Hodgkin's lymphomas: A historical perspective. <i>Seminars in Oncology</i> , 2003, 30, 10-21.	0.8	10
316	Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL. <i>Hematological Oncology</i> , 2003, 21, 99-108.	0.8	7
317	Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab. <i>American Journal of Hematology</i> , 2003, 73, 37-40.	2.0	11
318	Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. <i>Arthritis and Rheumatism</i> , 2003, 48, 3253-3265.	6.7	435
319	Primary cutaneous lymphomas: a review with current treatment options. <i>Blood Reviews</i> , 2003, 17, 131-142.	2.8	40
320	Monoclonal antibody therapy for lymphoma. <i>Blood Reviews</i> , 2003, 17, 143-152.	2.8	34

#	ARTICLE	IF	CITATIONS
321	Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 121, 44-48.	1.2	32
322	Delayed-onset neutropenia associated with rituximab therapy. <i>British Journal of Haematology</i> , 2003, 121, 913-918.	1.2	125
323	Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 122, 457-464.	1.2	73
324	Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 123, 271-277.	1.2	30
325	Phase I clinical trial of the bispecific antibody MDX-H210 (anti-Fc γ RII α — anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. <i>British Journal of Cancer</i> , 2003, 89, 2234-2243.	2.9	79
326	PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2003, 31, 467-473.	1.3	12
327	Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2003, 31, 775-782.	1.3	14
328	Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. <i>Leukemia</i> , 2003, 17, 900-909.	3.3	132
329	Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. <i>Leukemia</i> , 2003, 17, 1013-1034.	3.3	485
330	Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. <i>Leukemia</i> , 2003, 17, 1658-1664.	3.3	58
331	Tissue microarrays in drug discovery. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 962-972.	21.5	178
332	Intensive care unit outcomes in elderly cancer patients. <i>Critical Care Clinics</i> , 2003, 19, 657-675.	1.0	9
333	Unique Aspects of Supportive Care Using Monoclonal Antibodies in Cancer Treatment. <i>Supportive Cancer Therapy</i> , 2003, 1, 38-48.	0.3	38
334	Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. <i>Cytotherapy</i> , 2003, 5, 131-138.	0.3	57
335	Pediatric lung transplantation: update 2003. <i>Pediatric Clinics of North America</i> , 2003, 50, 1393-1417.	0.9	32
336	Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome. <i>Mayo Clinic Proceedings</i> , 2003, 78, 1340-1346.	1.4	149
337	Rituximab. <i>Drugs</i> , 2003, 63, 803-843.	4.9	412
338	Lymphomas and Oncolytic Virus Therapy. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 104-111.	2.1	4

#	ARTICLE	IF	CITATIONS
339	Rituximab in Lymphocyte Predominance Hodgkin's Disease: A Case Series. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 115-118.	2.1	11
340	High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin's Lymphoma: Results From the Randomized European CUP Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3918-3927.	0.8	458
341	Anti-CD20 Therapy for Chronic Lymphocytic Leukemia-associated Autoimmune Diseases. <i>Leukemia and Lymphoma</i> , 2003, 44, 1951-1955.	0.6	83
342	Non-Hodgkin lymphoma. <i>Lancet</i> , 2003, 362, 139-146.	6.3	122
343	Rituximab therapy for multisystem autoimmune diseases in pediatric patients. <i>Journal of Pediatrics</i> , 2003, 143, 598-604.	0.9	53
344	Monoclonal Antibody Therapy for Cancer. <i>Annual Review of Medicine</i> , 2003, 54, 343-369.	5.0	175
345	Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). <i>Blood</i> , 2003, 101, 6-14.	0.6	549
346	Endobronchial post-transplant lymphoproliferative disorder and its management with photodynamic therapy: a case report. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 474-477.	0.3	4
347	Indolent B-Cell Malignancies: Immune Recognition and Antiself. <i>Leukemia and Lymphoma</i> , 2003, 44, S77-S83.	0.6	0
348	Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. <i>Arthritis Research</i> , 2003, 5, S12.	2.0	57
349	B cells as a therapeutic target in autoimmune disease. <i>Arthritis Research</i> , 2003, 5, 131.	2.0	16
350	Spotlight on Rituximab in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. <i>American Journal of Cancer</i> , 2003, 2, 283-289.	0.4	0
351	Antibodies as therapeutic agents: vive la renaissance!. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 1133-1152.	1.4	73
352	Severe Autoimmune Hemolytic Anemia Following Rituximab Therapy in a Patient with a Lymphoproliferative Disorder. <i>Leukemia and Lymphoma</i> , 2003, 44, 889-890.	0.6	30
353	Combined Fludarabine and Rituximab for Low Grade Lymphoma and Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 477-481.	0.6	29
354	Adding Cytokines to Monoclonal Antibody Therapy: Does the Concurrent Administration of Interleukin-12 Add to the Efficacy of Rituximab in B-cell Non-Hodgkin Lymphoma?. <i>Leukemia and Lymphoma</i> , 2003, 44, 1309-1315.	0.6	15
356	An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. <i>Annals of Oncology</i> , 2003, 14, 520-535.	0.6	261
357	Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3051-3059.	0.8	245

#	ARTICLE	IF	CITATIONS
358	Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349). <i>Journal of Clinical Oncology</i> , 2003, 21, 2466-2473.	0.8	71
359	Immunotherapy in Systemic Primary (AL) Amyloidosis Using Amyloid-Reactive Monoclonal Antibodies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 853-860.	0.7	61
360	Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 1874-1881.	0.8	69
361	Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as <i>in vivo</i> purge and consolidative immunotherapy following autologous stem cell transplantation. <i>Annals of Oncology</i> , 2003, 14, 758-765.	0.6	31
362	T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct. <i>Journal of Immunology</i> , 2003, 170, 4397-4402.	0.4	183
363	Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2003, 14, i5-i10.	0.6	93
364	Differential chemokine, chemokine receptor, cytokine and cytokine receptor expression in pulmonary adenocarcinoma: Diffuse down-regulation is associated with immune evasion and brain metastasis. <i>International Journal of Oncology</i> , 2003, 23, 965.	1.4	6
365	Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. <i>Brain</i> , 2003, 126, 1409-1418.	3.7	497
366	Rituximab (Rituxan®/MabThera®): the first decade (1993-2003). <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 767-779.	1.1	57
367	Induction of Long-Term Remission of a Relapsed Childhood B-Cell Acute Lymphoblastic Leukemia With Rituximab Chimeric Anti-CD20 Monoclonal Antibody and Autologous Stem Cell Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 327-329.	0.3	33
368	Title is missing!. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 408-410.	0.6	4
369	Successful Treatment of Refractory Low Grade Duodenal Lymphoma With Rituximab, an Anti-cd20 Monoclonal Antibody. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 408-410.	0.6	8
371	Posttransplantation Lymphoproliferative Disorders. <i>Archives of Internal Medicine</i> , 2003, 163, 1997.	4.3	79
372	Infections in Patients with Hematological Cancer: Recent Developments. <i>Hematology American Society of Hematology Education Program</i> , 2003, 2003, 438-472.	0.9	93
373	In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. <i>Blood</i> , 2003, 101, 949-954.	0.6	333
374	An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. <i>Blood</i> , 2003, 101, 1071-1079.	0.6	144
375	Efficacy and safety of rituximab in type II mixed cryoglobulinemia. <i>Blood</i> , 2003, 101, 3827-3834.	0.6	471
376	Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2003, 102, 3514-3520.	0.6	125

#	ARTICLE	IF	CITATIONS
377	Rituximab in relapsed or refractory hairy cell leukemia. <i>Blood</i> , 2003, 102, 3906-3911.	0.6	155
378	Life-Threatening Bleeding from Refractory Acquired FVIII Inhibitor Successfully Treated with Rituximab. <i>Acta Haematologica</i> , 2003, 109, 206-208.	0.7	24
379	Monoclonal antibodies in the treatment of cancer, part 1. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 1531-1548.	0.5	34
381	Antibody Therapy of Lymphoma. <i>Advances in Pharmacology</i> , 2004, 51, 229-253.	1.2	8
382	Rituximab Followed by Cladribine in the Treatment of Heavily Pretreated Patients with Indolent Lymphoid Malignancies. <i>Leukemia and Lymphoma</i> , 2004, 45, 937-944.	0.6	29
383	Monoclonal antibody therapy of B cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 375-385.	1.4	20
384	Apoptosis as a tool for therapeutic agents in haematological diseases. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 407-420.	1.4	11
385	Antilymphoma Effects of Anti-HLA-DR and CD20 Monoclonal Antibodies (Lym-1 and Rituximab) on Human Lymphoma Cells. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 545-561.	0.7	17
386	In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2â€²-Deacetyl-N2â€²-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells. <i>Cancer Research</i> , 2004, 64, 4629-4636.	0.4	157
387	Phase I Study of Rituximab-CHOP Regimen in Combination with Granulocyte Colony-Stimulating Factor in Patients with Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2004, 10, 4077-4082.	3.2	31
388	The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2004, 10, 7792-7798.	3.2	142
389	Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide. <i>British Journal of Rheumatology</i> , 2004, 43, 1451-1452.	2.5	21
390	The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptorâ€”dependent Mechanisms during Anti-CD20 Antibody Immunotherapy. <i>Journal of Experimental Medicine</i> , 2004, 199, 1659-1669.	4.2	586
391	Monoclonal Antibody Therapy in Lymphoid Leukemias. <i>Advances in Pharmacology</i> , 2004, 51, 127-167.	1.2	2
392	Management of Lupus Nephritis: An Update. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2694-2704.	3.0	69
393	Treatment of a Patient with Chronic Immune Thrombocytopenic Purpura with Rituximab and Monitoring by Flow Cytometric Analysis. <i>Acta Haematologica</i> , 2004, 111, 221-224.	0.7	6
394	A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion. <i>British Journal of Rheumatology</i> , 2004, 43, 1450-1451.	2.5	52
395	Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkinâ€™s Lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 1469-1479.	0.8	109

#	ARTICLE	IF	CITATIONS
396	Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. <i>Annals of Oncology</i> , 2004, 15, 504-510.	0.6	45
397	The Role of B Cell-Mediated T Cell Costimulation in the Efficacy of the T Cell Retargeting Bispecific Antibody BIS20x3. <i>Journal of Immunology</i> , 2004, 173, 6009-6016.	0.4	2
398	Handbook of Cancer Vaccines. , 2004, , .		5
399	Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1. <i>Clinical Cancer Research</i> , 2004, 10, 16-18.	3.2	51
400	Cellular Immunotherapy for Follicular Lymphoma Using Genetically Modified CD20-Specific CD8+ Cytotoxic T Lymphocytes. <i>Molecular Therapy</i> , 2004, 9, 577-586.	3.7	78
401	Gallium nitrate for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 531-541.	1.9	53
402	Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2004, 10, 2868-2878.	3.2	168
403	Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases. <i>Annual Review of Medicine</i> , 2004, 55, 477-503.	5.0	203
404	Mouse CD20 expression and function. <i>International Immunology</i> , 2004, 16, 119-129.	1.8	212
405	The Natural History of CLL. , 2004, , 3-54.		1
406	Monoclonal antibodies as effective therapeutic agents for solid tumors. <i>Cancer Science</i> , 2004, 95, 621-625.	1.7	52
407	The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2004, 125, 232-239.	1.2	289
408	Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2004, 125, 414-415.	1.2	40
409	Pro-apoptotic therapy with the oligonucleotide Genasense™ (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. <i>British Journal of Haematology</i> , 2004, 127, 519-530.	1.2	39
410	Antibody-targeted radiation cancer therapy. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 488-499.	21.5	328
411	A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2004, 34, 175-179.	1.3	19
412	Plasmapheresis, CMV Hyperimmune Globulin, and Anti-CD20 Allow ABO-Incompatible Renal Transplantation Without Splenectomy. <i>American Journal of Transplantation</i> , 2004, 4, 1315-1322.	2.6	267
413	Targeted gene therapy: frontiers in the development of 'smart drugs?'. <i>Trends in Biotechnology</i> , 2004, 22, 304-310.	4.9	19

#	ARTICLE	IF	CITATIONS
414	Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. <i>Journal of Controlled Release</i> , 2004, 97, 1-17.	4.8	184
415	The Malignant Side of Successful Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 153-154.	2.6	5
416	Apoptosis in cancerâ€™s implications for therapy. <i>Seminars in Oncology</i> , 2004, 31, 90-119.	0.8	134
417	HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells. <i>Gynecologic Oncology</i> , 2004, 95, 290-298.	0.6	20
418	Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. <i>Pathology International</i> , 2004, 54, 667-674.	0.6	22
419	Fludarabine- and Cyclophosphamide-Based Nonmyeloablative Conditioning Regimen for Transplantation of Chronic Granulomatous Disease: Possible Correlation with Prolonged Pure Red Cell Aplasia. <i>International Journal of Hematology</i> , 2004, 79, 293-297.	0.7	5
420	Acute Respiratory Distress Syndrome during the Third Infusion of Rituximab in a Patient with Follicular Lymphoma. <i>International Journal of Hematology</i> , 2004, 80, 164-167.	0.7	22
421	Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin's Lymphomas: Results of a Japanese Phase II Study. <i>International Journal of Hematology</i> , 2004, 80, 267-277.	0.7	40
422	Pharmacogenetic Problems of Antitumor Therapy (A Review). <i>Pharmaceutical Chemistry Journal</i> , 2004, 38, 347-354.	0.3	0
423	Apoptosis Induced by Molecular Targeting Therapy in Hematological Malignancies. <i>Acta Haematologica</i> , 2004, 111, 107-123.	0.7	16
424	Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. <i>Pediatric Nephrology</i> , 2004, 19, 794-797.	0.9	170
426	CD64 Surface Expression on Neutrophils and Monocytes Is Significantly Up-Regulated after Stimulation with Granulocyte Colony-Stimulating Factor during CHOP Chemotherapy for Patients with Non-Hodgkin's Lymphoma. <i>International Journal of Hematology</i> , 2004, 79, 55-62.	0.7	21
428	Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt's lymphoma. <i>Annals of Hematology</i> , 2004, 83, 120-123.	0.8	12
429	Successful treatment of B-cell polymphocytic leukemia with monoclonal anti-CD20 antibody. <i>Annals of Hematology</i> , 2004, 83, 319-321.	0.8	28
430	Three-dimensional structures of a humanized anti-IFN- β Fab (HuZAF) in two crystal forms. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2004, 60, 1761-1769.	2.5	8
431	Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. <i>British Journal of Haematology</i> , 2004, 124, 309-314.	1.2	58
432	Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. <i>American Journal of Hematology</i> , 2004, 77, 303-310.	2.0	34
433	The role of fludarabine in the treatment of follicular and mantle cell lymphoma. <i>Cancer</i> , 2004, 101, 883-893.	2.0	31

#	ARTICLE	IF	CITATIONS
434	Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells. <i>International Journal of Cancer</i> , 2004, 110, 741-750.	2.3	83
435	Antibody Pharmacokinetics and Pharmacodynamics. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2645-2668.	1.6	804
436	Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 1274-1287.	0.4	70
437	Enhanced Cytotoxicity of Rituximab Following Genetic and Biochemical Disruption of Glycosylphosphatidylinositol Anchored Proteins. <i>Leukemia and Lymphoma</i> , 2004, 45, 795-800.	0.6	16
438	Analisi costo-efficacia di rituximab + CHOP versus CHOP in soggetti affetti da linfoma non-Hodgkin aggressivo. <i>Pharmacoeconomics Italian Research Articles</i> , 2004, 6, 151-160.	0.2	7
439	Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression. <i>Leukemia and Lymphoma</i> , 2004, 45, 2057-2061.	0.6	39
440	Lymphomes folliculaires. <i>EMC - Hematologie</i> , 2004, 1, 83-105.	0.1	1
441	Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. <i>New England Journal of Medicine</i> , 2004, 351, 2159-2169.	13.9	1,293
442	Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal) Tj ETQq0 0 0 rgBT /Overlock 10 T alone. <i>Scandinavian Journal of Rheumatology</i> , 2004, 33, 423-427.	0.6	91
443	The rationale for and background of radioimmunotherapy: an emerging therapy for B-cell non-hodgkin's lymphoma. <i>Seminars in Oncology Nursing</i> , 2004, 20, 1-7.	0.7	1
444	In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. <i>Human Antibodies</i> , 2004, 13, 55-62.	0.6	78
445	Monoclonal Antibody Treatment of Orbital Lymphoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2004, 20, 103-106.	0.4	50
446	Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. <i>Blood</i> , 2004, 103, 3516-3520.	0.6	33
447	Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. <i>Blood</i> , 2004, 103, 4416-4423.	0.6	531
448	The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. <i>Blood</i> , 2004, 104, 3064-3071.	0.6	558
450	Cell Cycle and Growth Control: Current Clinical Applications. , 2004, , 667-703.		2
451	Successful Treatment of Diffuse Large B-cell Lymphoma Following Waldenstroem's Macroglobulinemia with CHOP Chemotherapy Followed by Combination Therapy of CHOP with Rituximab. <i>Internal Medicine</i> , 2004, 43, 131-134.	0.3	5
452	Orbital Lymphoma. , 2005, , 133-140.		4

#	ARTICLE	IF	CITATIONS
453	Rituximab: Clinical Development of the First Therapeutic Antibody for Cancer. , 2005, , 211-229.		1
454	An anti-CD20â€“IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. <i>Blood</i> , 2005, 105, 3972-3978.	0.6	83
455	Is antibody therapy of tumor compromised by infusion-related reactions?. <i>Leukemia Research</i> , 2005, 29, 239-246.	0.4	4
456	Infections associated with purine analogs and monoclonal antibodies. <i>Blood Reviews</i> , 2005, 19, 253-273.	2.8	19
457	Overview of monoclonal antibodies in cancer therapy: present and promise. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 54, 11-29.	2.0	201
458	Cost-Effectiveness Analysis of Rituximab Combined with CHOP for Treatment of Diffuse Large B-Cell Lymphoma. <i>Value in Health</i> , 2005, 8, 462-470.	0.1	40
459	Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma. <i>British Journal of Dermatology</i> , 2005, 152, 541-544.	1.4	46
460	Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - an applicational observation. <i>British Journal of Dermatology</i> , 2005, 153, 167-173.	1.4	64
461	New therapies for rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2005, 140, 195-204.	1.1	70
462	Ascitic complement system in ovarian cancer. <i>British Journal of Cancer</i> , 2005, 92, 895-905.	2.9	110
463	Stable antibody expression at therapeutic levels using the 2A peptide. <i>Nature Biotechnology</i> , 2005, 23, 584-590.	9.4	358
464	Monoclonal antibody therapy of cancer. <i>Nature Biotechnology</i> , 2005, 23, 1147-1157.	9.4	1,068
465	Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. <i>Leukemia</i> , 2005, 19, 1648-1655.	3.3	62
466	Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas. <i>Oncogene</i> , 2005, 24, 6201-6212.	2.6	116
467	The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 616-621.	0.7	28
468	Concepts in radiotherapy and immunotherapy: Anti-CD20 mechanisms of action and targets. <i>Seminars in Oncology</i> , 2005, 32, 19-26.	0.8	21
469	Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. <i>European Journal of Haematology</i> , 2005, 75, 527-529.	1.1	35
470	Delayed-Onset Grade 4 Neutropenia Associated with Rituximab Therapy in a Patient with Lymphoma: Case Report and Literature Review. <i>Pharmacotherapy</i> , 2005, 25, 1151-1155.	1.2	14

#	ARTICLE	IF	CITATIONS
471	Paraneoplastic cerebellar degeneration with fallopian tube adenocarcinoma. <i>Gynecologic Oncology</i> , 2005, 99, 500-503.	0.6	18
472	Patterns of care in a population-based random sample of patients diagnosed with non-Hodgkin's lymphoma. <i>Hematological Oncology</i> , 2005, 23, 73-81.	0.8	33
473	The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. <i>Cancer</i> , 2005, 104, 2743-2752.	2.0	45
474	Rituximab and Wegener's granulomatosis: Are B cells a target in vasculitis treatment?. <i>Arthritis and Rheumatism</i> , 2005, 52, 1-5.	6.7	49
475	Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. <i>Arthritis and Rheumatism</i> , 2005, 52, 2740-2750.	6.7	462
476	Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab. <i>American Journal of Hematology</i> , 2005, 78, 138-141.	2.0	22
477	Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2005, 78, 275-280.	2.0	121
478	Expression and characterisation of recombinant human CD48 and isolation of a human anti-CD48 monoclonal antibody by phage display. <i>Journal of Chemical Technology and Biotechnology</i> , 2005, 80, 782-795.	1.6	4
479	Repeated injections of ¹³¹ I-rituximab show patient-specific stable biodistribution and tissue kinetics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 943-951.	3.3	7
480	Current status of monoclonal antibodies as therapeutic agents for solid cancer. <i>Journal of Gastroenterology</i> , 2005, 40, 1009-1011.	2.3	1
481	Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab. <i>International Journal of Clinical Oncology</i> , 2005, 10, 357-361.	1.0	23
483	Clinical Studies of Immunotherapy With Rituximab (Rituxan®) and Radioimmunotherapy With Ibritumomab Tiuxetan (Zevalin®) in B-Cell Lymphoid Malignancies. , 2005, , 677-709.		0
484	Depleção de células B no tratamento de citopenias auto-imunes. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2005, 27, 102.	0.7	1
485	Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti-Helicobacter Pylori Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 1979-1983.	0.8	265
486	The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice. <i>Journal of Immunology</i> , 2005, 174, 4389-4399.	0.4	204
487	Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple Myeloma. <i>Cancer Research</i> , 2005, 65, 5898-5906.	0.4	146
488	Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. <i>Blood</i> , 2005, 106, 3725-3732.	0.6	1,221
489	Cyclophosphamide Inhibition of Anti-CD40 Monoclonal Antibody-Based Therapy of B Cell Lymphoma Is Dependent on CD11b+ Cells. <i>Cancer Research</i> , 2005, 65, 7493-7501.	0.4	9

#	ARTICLE	IF	CITATIONS
490	Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 694-704.	0.8	140
491	Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 1103-1108.	0.8	187
492	Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 7024-7031.	0.8	195
493	Persistent Panhypogammaglobulinemia After CHOP-Rituximab for HIV-Related Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 247-248.	0.8	54
494	Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?. <i>Annals of the Rheumatic Diseases</i> , 2005, 65, 841-844.	0.5	20
495	Paracrine Inhibition of Prion Propagation by Anti-PrP Single-Chain Fv Mini-antibodies. <i>Journal of Virology</i> , 2005, 79, 8330-8338.	1.5	73
496	Reactivation of hepatitis B virus with rituximab. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 599-608.	1.0	130
497	How does B cell depletion therapy work, and how can it be improved?. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, iv77-iv80.	0.5	26
498	B cells as a therapeutic target in autoimmune diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 431-445.	1.5	10
499	Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms. <i>Journal of Immunology</i> , 2005, 174, 7859-7868.	0.4	41
500	Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network. <i>Journal of Clinical Oncology</i> , 2005, 23, 1088-1095.	0.8	315
501	Inactivation of Myc in Murine Two-Hit B lymphomas Causes Dormancy with Elevated Levels of Interleukin 10 Receptor and CD20: Implications for Adjuvant Therapies. <i>Cancer Research</i> , 2005, 65, 5454-5461.	0.4	29
502	Phase II Trial of Individualized Rituximab Dosing for Patients With CD20-Positive Lymphoproliferative Disorders. <i>Journal of Clinical Oncology</i> , 2005, 23, 1096-1102.	0.8	124
503	Treatment Strategies in Follicular Lymphomas: Current Status and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2005, 23, 6394-6399.	0.8	80
504	Minimizing the Immunogenicity of Antibodies for Clinical Application. <i>Tumor Biology</i> , 2005, 26, 31-43.	0.8	40
505	Molecular target therapy for synovial sarcoma. <i>Future Oncology</i> , 2005, 1, 805-812.	1.1	10
506	Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3383-3389.	0.8	412
507	Immunotherapy and immunoprevention of cancer: where do we stand?. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 717-726.	1.4	6

#	ARTICLE	IF	CITATIONS
508	Targeted therapies for prostate cancer. Expert Opinion on Therapeutic Targets, 2005, 9, 283-298.	1.5	12
509	Post-Transplant Lymphoproliferative Disorder in Children. Paediatric Drugs, 2005, 7, 55-65.	1.3	44
510	The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling. Advances in Immunology, 2005, 87, 163-208.	1.1	218
511	Treatment of primary cutaneous B-cell lymphoma with rituximab. Journal of the American Academy of Dermatology, 2005, 52, 847-853.	0.6	89
512	Tolerability and safety of rituximab (MabThera®). Cancer Treatment Reviews, 2005, 31, 456-473.	3.4	442
513	Characterization of lymphocyte populations in nonspecific interstitial pneumonia*. Respiratory Research, 2005, 6, 137.	1.4	18
514	Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?. Arthritis Research, 2005, 7, S15.	2.0	22
516	Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments. Leukemia and Lymphoma, 2006, 47, 1013-1017.	0.6	124
517	Letters to the Editor. Leukemia and Lymphoma, 2006, 47, 747-775.	0.6	14
518	Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Review of Anticancer Therapy, 2006, 6, 1175-1186.	1.1	35
519	Monoclonal Antibody Therapy for Hairy Cell Leukemia. Hematology/Oncology Clinics of North America, 2006, 20, 1125-1136.	0.9	9
521	Implications of cancer stem cells in the treatment of cancer. Future Oncology, 2006, 2, 723-731.	1.1	36
522	Antibody isotype-specific engagement of Fcγ3 receptors regulates B lymphocyte depletion during CD20 immunotherapy. Journal of Experimental Medicine, 2006, 203, 743-753.	4.2	238
523	Treatment and survival for non-Hodgkin's lymphoma: Influence of histological subtype, age, and other factors in a population-based study (1999-2001). European Journal of Cancer, 2006, 42, 2786-2793.	1.3	22
524	Rituximab as Monotherapy for Elicited Xenoreactive Antibody Responses. Journal of Heart and Lung Transplantation, 2006, 25, 1462-1466.	0.3	11
525	Transplantation of the highly human leukocyte antigen-sensitized patient: long-term outcomes and future directions. Transplantation Reviews, 2006, 20, 146-156.	1.2	14
526	Cancer therapy with engineered monoclonal antibodies. Update on Cancer Therapeutics, 2006, 1, 147-157.	0.9	11
527	ABO-Incompatible Solid-Organ Transplantation. Pathology Patterns Reviews, 2006, 125, S87-S94.	0.4	19

#	ARTICLE	IF	CITATIONS
528	Radioisotopes and Radioimmunoisotopes. , 2006, , 301-312.		0
531	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 2006, 107, 2639-2642.	0.6	204
533	Rituximab in Refractory Wegener's Granulomatosis: Favorable or Not?. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 816-816.	2.5	9
535	Therapy With Immunoglobulin. Journal of Infusion Nursing, 2006, 29, S29-S44.	1.2	3
536	Rituximab (anti-CD20) Adjunctive Therapy for Opsoclonus-Myoclonus Syndrome. Journal of Pediatric Hematology/Oncology, 2006, 28, 585-593.	0.3	120
537	Clinical Features and Management of Tumors Affecting the Lacrimal Drainage Apparatus. Ophthalmic Plastic and Reconstructive Surgery, 2006, 22, 96-101.	0.4	45
538	Emerging Monoclonal Antibody Therapies for Multiple Sclerosis. Neurologist, 2006, 12, 171-178.	0.4	44
539	Immunophenotypic Changes and Clinical Outcome in B-Cell Lymphomas Treated with Rituximab. Applied Immunohistochemistry and Molecular Morphology, 2006, 14, 18-23.	0.6	35
540	Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 69-74.	1.3	66
541	Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. British Journal of Haematology, 2006, 133, 3-18.	1.2	29
542	Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer, 2006, 6, 714-727.	12.8	661
543	Rituximab: Applications in dermatology. International Journal of Dermatology, 2006, 45, 1143-1155.	0.5	33
544	Cure of incurable lymphoma. International Journal of Radiation Oncology Biology Physics, 2006, 66, S46-S56.	0.4	25
545	Fc γ 3 receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Seminars in Immunopathology, 2006, 28, 351-364.	4.0	57
546	Rituximab (Anti-CD20 Monoclonal Antibody) in Children with Chronic Refractory Symptomatic Immune Thrombocytopenic Purpura: Efficacy and Safety of Treatment. International Journal of Hematology, 2006, 84, 48-53.	0.7	35
547	Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1013-1023.	2.2	42
548	Dramatical improvement of chemoresistant bone lymphoma with rituximab. Clinical Rheumatology, 2006, 25, 394-395.	1.0	7
549	Preliminary outcome of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma: single institution experience. Chinese-German Journal of Clinical Oncology, 2006, 5, 402-406.	0.1	0

#	ARTICLE	IF	CITATIONS
550	Monoclonal antibody therapy of chronic lymphocytic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 188-196.	2.0	44
551	Immune defects in patients with chronic lymphocytic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 197-209.	2.0	117
552	Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. <i>Annals of Hematology</i> , 2006, 85, 400-406.	0.8	87
553	Satellite Symposia and Meet-the-Professor Sessions. <i>Annals of Hematology</i> , 2006, 85, 28-126.	0.8	2
554	Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2006, 85, 769-779.	0.8	13
555	Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. <i>Annals of Hematology</i> , 2006, 86, 95-100.	0.8	32
556	Nodular B-Cell Aggregates Associated with Treatment Refractory Renal Transplant Rejection Resolved by Rituximab. <i>American Journal of Transplantation</i> , 2006, 6, 847-851.	2.6	62
557	Novel ligands for cancer diagnosis: Selection of peptide ligands for identification and isolation of B-cell lymphomas. <i>Experimental Hematology</i> , 2006, 34, 443-452.	0.2	34
558	Development of antibody-based therapeutics for oncology indications. <i>Drug Development Research</i> , 2006, 67, 699-728.	1.4	3
559	Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-hodgkin lymphoma. <i>Cancer</i> , 2006, 106, 2412-2420.	2.0	85
560	Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. <i>Hematological Oncology</i> , 2006, 24, 234-237.	0.8	43
561	Delayed Reduction in Left Ventricular Function following Treatment of Non-Hodgkin's Lymphoma with Chemotherapy and Rituximab, Unrelated to Acute Infusion Reaction. <i>Cardiology</i> , 2006, 105, 184-187.	0.6	23
562	Signaling Abnormalities in Systemic Lupus Erythematosus as Potential Drug Targets. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2006, 6, 305-311.	0.6	20
563	Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2320-2324.	0.4	17
564	Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence?. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 32-36.	0.4	23
565	Rituximab in Refractory Wegener's Granulomatosis: Favorable or Not?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 815a-816.	2.5	9
566	Recombinant Antibodies in Cancer Therapy. <i>Current Protein and Peptide Science</i> , 2006, 7, 165-170.	0.7	6
567	Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity. <i>Clinical Cancer Research</i> , 2006, 12, 4027-4035.	3.2	217

#	ARTICLE	IF	CITATIONS
568	Long-Term Multiple-Dose Pharmacokinetics of Human Monoclonal Antibodies (MAbs) against Human Immunodeficiency Virus Type 1 Envelope gp120 (MAB 2G12) and gp41 (MAbs 4E10 and 2F5). <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1773-1779.	1.4	63
569	Current treatment strategies in follicular lymphomas. <i>Annals of Oncology</i> , 2006, 17, x155-x159.	0.6	5
570	Rituximab Can Be Combined With Daily Plasma Exchange to Achieve Effective B-Cell Depletion and Clinical Improvement in Acute Autoimmune TTP. <i>American Journal of Clinical Pathology</i> , 2006, 125, 592-597.	0.4	45
571	Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients. <i>Clinical Cancer Research</i> , 2006, 12, 6056-6063.	3.2	52
572	The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes. <i>Journal of Immunology</i> , 2006, 176, 2600-2609.	0.4	203
573	Current pharmacotherapy for the treatment of crescentic glomerulonephritis. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 1353-1369.	1.9	11
574	A Quantitative Exploration of Surface Antigen Expression in Common B-Cell Malignancies Using Flow Cytometry. <i>Immunological Investigations</i> , 2006, 35, 93-114.	1.0	118
575	Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. <i>Cancer Investigation</i> , 2006, 24, 593-600.	0.6	55
576	Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. <i>Leukemia and Lymphoma</i> , 2006, 47, 1902-1907.	0.6	27
577	REFRACTORINESS TO RITUXIMAB MONOTHERAPY IN A CHILD WITH RELAPSED/REFRACTORY BURKITT NON-HODGKIN LYMPHOMA. <i>Pediatric Hematology and Oncology</i> , 2006, 23, 25-31.	0.3	6
578	Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2006, 177, 7435-7443.	0.4	141
579	Cosecretion of Protease Inhibitor Stabilizes Antibodies Produced by Plant Roots. <i>Plant Physiology</i> , 2006, 141, 1185-1193.	2.3	115
580	Rituximab and nephrotic syndrome: a new therapeutic hope?. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 11-17.	0.4	22
581	Cancer du sujet ÂçgÃ©. , 2007, , .		1
582	A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 4071-4076.	3.3	203
583	Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4730-4735.	0.8	359
584	Pathogenesis of Graves' Ophthalmopathy: The Role of Autoantibodies. <i>Thyroid</i> , 2007, 17, 1013-1018.	2.4	132
585	Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 959-965.	1.1	7

#	ARTICLE	IF	CITATIONS
586	An Update on Monoclonal Antibody Therapies in Multiple Sclerosis. <i>Journal of Pharmacy Practice</i> , 2007, 20, 167-180.	0.5	1
587	A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen. <i>Clinical Cancer Research</i> , 2007, 13, 3286-3292.	3.2	63
588	Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. <i>Leukemia and Lymphoma</i> , 2007, 48, 431-433.	0.6	37
589	Evolving Therapies For Multiple Sclerosis. <i>International Review of Neurobiology</i> , 2007, 79, 571-588.	0.9	5
590	Clinical utilization of chemokines to combat cancer: the double-edged sword. <i>Expert Review of Vaccines</i> , 2007, 6, 267-283.	2.0	41
591	What influence has B-cell depletion on viral infections?. <i>Leukemia and Lymphoma</i> , 2007, 48, 1257-1258.	0.6	3
592	Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1799-1815.	1.9	5
593	Effect of Antilymphoma Antibody,131I-Lym-1, on Peripheral Blood Lymphocytes in Patients with Non-Hodgkin's Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 521-530.	0.7	2
594	Phase I to III Trials of Anti-B Cell Therapy in Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2007, 13, 5636s-5642s.	3.2	13
595	Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy. <i>Cancer Research</i> , 2007, 67, 2872-2880.	0.4	37
596	Spleen Tyrosine Kinase (Syk), a Novel Target of Curcumin, Is Required for B Lymphoma Growth. <i>Journal of Immunology</i> , 2007, 178, 111-121.	0.4	83
597	A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non-Hodgkin's Lymphoma: A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2007, 13, 5652s-5660s.	3.2	31
598	Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. <i>Rheumatology</i> , 2007, 46, 29-36.	0.9	86
599	Toll-like Receptors in Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 5280-5289.	3.2	114
600	Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models. <i>Journal of Immunology</i> , 2007, 179, 4263-4271.	0.4	65
601	Biological therapies: new treatment options for ANCA-associated vasculitis?. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 521-533.	1.4	12
602	Bilateral Conjunctivitis Due to Rituximab. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1318-1318.	0.9	14
604	Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. <i>Blood</i> , 2007, 110, 4037-4046.	0.6	94

#	ARTICLE	IF	CITATIONS
605	Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura. <i>Annals of Internal Medicine</i> , 2007, 146, 25.	2.0	477
607	Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab. <i>Mayo Clinic Proceedings</i> , 2007, 82, 692-699.	1.4	32
609	Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. <i>American Journal of Geriatric Pharmacotherapy</i> , 2007, 5, 247-262.	3.0	15
610	Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. <i>International Immunopharmacology</i> , 2007, 7, 1064-1075.	1.7	65
611	Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). <i>Journal of the American Academy of Dermatology</i> , 2007, 56, e55-e79.	0.6	101
612	New Agents in Development for Non-Hodgkin's Lymphoma. <i>Seminars in Hematology</i> , 2007, 44, S18-S21.	1.8	0
613	Primary mediastinal large B-cell lymphoma: a retrospective analysis of rituximab and CHOP chemotherapy. <i>Community Oncology</i> , 2007, 4, 673-677.	0.2	2
614	Apoptosis, Senescence, and Cancer. , 2007, , .		8
615	General Principles of Tumor Immunotherapy. , 2007, , .		3
616	Monoclonal Antibody Targeted Radiation Cancer Therapy. , 2007, , 50-58.		0
617	David Galton, myelodysplasia and little me!. <i>Leukemia and Lymphoma</i> , 2007, 48, 2286-2287.	0.6	0
618	Distinguishing between entities "rationally based advances in the therapy of follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2285-2286.	0.6	0
619	Lym-1-Induced Apoptosis of Non-Hodgkin's Lymphomas Produces Regression of Transplanted Tumors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 342-356.	0.7	8
620	Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2007, 13, 6168-6174.	3.2	111
621	Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 235-244.	1.5	75
622	Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab. <i>Mayo Clinic Proceedings</i> , 2007, 82, 692-699.	1.4	31
623	Biologic therapies: what and when?. <i>Journal of Clinical Pathology</i> , 2007, 60, 8-17.	1.0	22
624	Rituximab in mixed cryoglobulinemia: increased experience and perspectives. <i>Digestive and Liver Disease</i> , 2007, 39, S122-S128.	0.4	32

#	ARTICLE	IF	CITATIONS
625	Lymphomes et autres tumeurs h�matologiques. , 2007, , 179-206.		1
626	Potential applications of designed ankyrin repeat proteins in diagnostics and therapeutics. Expert Opinion on Medical Diagnostics, 2007, 1, 409-421.	1.6	4
628	Improvement of Sj�gren's syndrome after two infusions of rituximab (anti-CD20). Arthritis and Rheumatism, 2007, 57, 310-317.	6.7	280
629	Six refractory lupus patients treated with rituximab: A case series. Arthritis and Rheumatism, 2007, 57, 538-542.	6.7	37
630	Age disparity between a cancer population and participants in clinical trials submitted as a new drug application of anticancer drugs in Japan. Cancer, 2007, 109, 2541-2546.	2.0	12
631	Current management of follicular lymphomas. British Journal of Haematology, 2007, 136, 191-202.	1.2	27
632	High activity ⁹⁰ Y-ibritumomab tiuxetan (Zevalin [�]) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. British Journal of Haematology, 2007, 139, 590-599.	1.2	45
633	Off-label uses of rituximab in dermatology. Dermatologic Therapy, 2007, 20, 277-287.	0.8	32
634	Autoimmune disease etiology�a perplexing paradox or a turning leaf?. Autoimmunity Reviews, 2007, 6, 204-208.	2.5	9
635	One target�multiple indications: a call for an integrated common mechanisms strategy. Drug Discovery Today, 2007, 12, 1025-1031.	3.2	20
636	Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response. European Journal of Haematology, 2007, 79, 546-549.	1.1	12
637	An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. Journal of Immunological Methods, 2007, 327, 10-17.	0.6	139
638	Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy. International Journal of Hematology, 2007, 86, 49-57.	0.7	43
639	Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma. Current Hematologic Malignancy Reports, 2007, 2, 225-231.	1.2	1
640	Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunology, Immunotherapy, 2008, 57, 411-423.	2.0	192
641	The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatology International, 2008, 28, 205-215.	1.5	42
642	Observation of the curative effect of Mabthera in combination with the CHOP regimen in treating invasive B-cell lymphoma: A report of 45 cases. Chinese Journal of Clinical Oncology, 2008, 5, 215-218.	0.0	0
643	B-Cell Depletion and Repopulation in Autoimmune Diseases. Clinical Reviews in Allergy and Immunology, 2008, 34, 50-55.	2.9	43

#	ARTICLE	IF	CITATIONS
644	Rituximab as a Therapeutic Tool in Severe Mixed Cryoglobulinemia. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 34, 111-117.	2.9	65
645	Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma. <i>Medical Oncology</i> , 2008, 25, 437-442.	1.2	29
646	Monoclonal antibodies in the therapy of multiple sclerosis. <i>Journal of Neurology</i> , 2008, 255, 28-35.	1.8	20
647	SEREX, Proteomex, AMIDA, and beyond: Serological screening technologies for target identification. <i>Proteomics - Clinical Applications</i> , 2008, 2, 355-371.	0.8	14
648	Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 2008, 112, 119-128.	2.0	86
649	Durable complete responses from therapy with combined epratuzumab and rituximab. <i>Cancer</i> , 2008, 113, 2714-2723.	2.0	102
650	The effects of rituximab on immunocompetency in patients with autoimmune disease. <i>Arthritis and Rheumatism</i> , 2008, 58, 5-14.	6.7	83
651	Abbreviated dose rituximab for immune-mediated hematological disorders. <i>American Journal of Hematology</i> , 2008, 83, 554-557.	2.0	11
652	Follicular lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 248-261.	2.0	44
653	Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2008, 359, 613-626.	13.9	412
654	Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?. <i>Bone Marrow Transplantation</i> , 2008, 42, 483-487.	1.3	20
655	Betting on B cells in multiple sclerosis. <i>Nature Medicine</i> , 2008, 14, 615-616.	15.2	1
656	Paul Ehrlich's magic bullet concept: 100 years of progress. <i>Nature Reviews Cancer</i> , 2008, 8, 473-480.	12.8	1,064
657	Protein therapeutics: a summary and pharmacological classification. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 21-39.	21.5	1,678
658	Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. <i>Cancer Science</i> , 2008, 99, 432-440.	1.7	68
659	Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of Fcγ3R/CD16. <i>British Journal of Haematology</i> , 2008, 140, 635-643.	1.2	115
660	Responses to Rituximab Vary Among Follicular Lymphoma B Cells of Different Maturation Stages. <i>Scandinavian Journal of Immunology</i> , 2008, 68, 159-168.	1.3	6
661	B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. <i>Journal of Neuroimmunology</i> , 2008, 204, 1-12.	1.1	26

#	ARTICLE	IF	CITATIONS
662	Acute Coronary Syndromes Complicating the First Infusion of Rituximab. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 253-255.	1.4	36
663	Autoimmune hemolytic anemia: classification and therapeutic approaches. <i>Expert Review of Hematology</i> , 2008, 1, 189-204.	1.0	20
664	Off-Label Use of Biologic Agents in the Treatment of Dermatitis, Part 2: Etanercept, Efalizumab, Alefacept, Rituximab, Daclizumab, Basiliximab, Omalizumab, and Cetuximab. <i>Actas Dermo-sifiliográficas</i> , 2008, 99, 5-33.	0.2	4
665	The NF- κ B inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. <i>Leukemia and Lymphoma</i> , 2008, 49, 1982-1994.	0.6	25
668	Identification and development of new therapeutics for multiple sclerosis. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 558-565.	4.0	61
669	High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 50-58.	2.0	94
672	Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 2116-2124.	0.6	11
673	Rituximab – a double-edged sword: can one treatment for thrombocytopenia also induce it?. <i>Leukemia and Lymphoma</i> , 2008, 49, 2035-2036.	0.6	1
674	Rituximab-Induced Severe Acute Thrombocytopenia: A case Report and Review of Literature. <i>Cancer Investigation</i> , 2008, 26, 913-915.	0.6	27
675	Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10131-10136.	3.3	173
676	A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function. <i>Clinical Cancer Research</i> , 2008, 14, 7935-7939.	3.2	29
677	Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3 ζ recombinant gene. <i>Leukemia and Lymphoma</i> , 2008, 49, 1368-1373.	0.6	19
678	Treatment of Neuromyelitis Optica With Rituximab. <i>Archives of Neurology</i> , 2008, 65, 1443.	4.9	445
679	Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis. <i>Journal of Immunology</i> , 2008, 181, 822-832.	0.4	116
680	Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving. <i>Journal of Immunology</i> , 2008, 181, 2916-2924.	0.4	86
681	Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance. <i>Cancer Research</i> , 2008, 68, 190-197.	0.4	495
682	CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2008, 14, 2775-2784.	3.2	491
683	Review: Innovative monoclonal antibody therapies in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2008, 1, 33-42.	1.5	22

#	ARTICLE	IF	CITATIONS
684	A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma. Annual Review of Medicine, 2008, 59, 237-250.	5.0	174
685	Radiation Therapy with Tositumomab (B1) Anti-CD20 Monoclonal Antibody Initiates Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase-Dependent Cell Death that Overcomes Resistance to Apoptosis. Clinical Cancer Research, 2008, 14, 4925-4934.	3.2	31
686	The Potential Effect of Statins on Rituximab Immunotherapy. PLoS Medicine, 2008, 5, e77.	3.9	7
687	Rituximab treatment of idiopathic membranous nephropathy. Kidney International, 2008, 73, 117-125.	2.6	219
688	Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression. Clinical Cancer Research, 2008, 14, 1550-1560.	3.2	107
689	GM-CSF plus rituximab immunotherapy: Translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leukemia and Lymphoma, 2008, 49, 1681-1692.	0.6	19
690	Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century. Archives of Internal Medicine, 2008, 168, 469.	4.3	78
691	B-Cell Non-Hodgkin Lymphoma: PET/CT Evaluation after ⁹⁰ Y- ¹²⁵ Ibrutinomab Tixetan Radioimmunotherapy Initial Experience ¹ . Radiology, 2008, 246, 895-902.	3.6	28
692	Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study. Journal of Clinical Oncology, 2008, 26, 2725-2731.	0.8	77
693	Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: Analysis of remission induction and stem cell mobilization. Leukemia and Lymphoma, 2008, 49, 1337-1344.	0.6	8
694	Internalisation of uncross-linked rituximab is not essential for the induction of caspase-independent killing in Burkitt lymphoma cell lines. Leukemia and Lymphoma, 2008, 49, 1578-1591.	0.6	2
695	Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood, 2008, 112, 830-835.	0.6	81
696	Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood, 2008, 112, 4824-4831.	0.6	304
697	A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies. Current Pharmaceutical Design, 2008, 14, 2085-2099.	0.9	16
698	Rituximab and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Journal of Clinical Rheumatology, 2008, 14, 61-64.	0.5	2
699	Pharmacokinetic Properties of Rituximab. Reviews on Recent Clinical Trials, 2008, 3, 22-30.	0.4	18
700	Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. OncoTargets and Therapy, 2009, 2, 229.	1.0	4
701	Expanded use of rituximab in the management of non-Hodgkin lymphoma. OncoTargets and Therapy, 2009, 2, 189.	1.0	4

#	ARTICLE	IF	CITATIONS
702	Dysregulation of the cell survival/anti-apoptotic NF- κ B pathway by the novel humanized BM-ca anti-CD20 mAb: Implication in chemosensitization. <i>International Journal of Oncology</i> , 2009, 35, 1289-96.	1.4	15
704	Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3036-3043.	0.8	132
705	Translating Molecular Insights in Autoimmunity into Effective Therapy. <i>Annual Review of Immunology</i> , 2009, 27, 1-27.	9.5	54
706	Rituximab and chemotherapy in diffuse large B-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 719-726.	1.1	11
707	A Case of Chronic Conjunctivitis following Rituximab Therapy. <i>Advances in Hematology</i> , 2009, 2009, 1-4.	0.6	2
708	Successful Treatment of Membranous Glomerulonephritis with Rituximab in Calcineurin Inhibitor-Dependent Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1083-1088.	2.2	76
709	Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. <i>Human Antibodies</i> , 2009, 18, 47-73.	0.6	43
710	Cetuximab Retargeting of Adenovirus via the Epidermal Growth Factor Receptor for Treatment of Intraperitoneal Ovarian Cancer. <i>Human Gene Therapy</i> , 2009, 20, 239-251.	1.4	37
711	Target chemotherapy of anti-CD147 antibody-labeled liposome encapsulated GSH-DXR conjugate on CD147 highly expressed carcinoma cells. <i>International Journal of Oncology</i> , 2009, 36, .	1.4	4
712	Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders. <i>Hematology</i> , 2009, 14, 187-197.	0.7	1
713	Screening for genetic abnormalities involved in ovarian carcinogenesis using retroviral expression libraries. <i>International Journal of Oncology</i> , 2009, 35, 973-6.	1.4	10
714	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1001-1011.	1.9	187
715	Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient. <i>Expert Review of Hematology</i> , 2009, 2, 173-182.	1.0	5
716	Prevention of hepatitis B virus reactivation under rituximab therapy. <i>Immunotherapy</i> , 2009, 1, 1053-1061.	1.0	14
717	Management of relapse and minimal residual disease after stem cell allotransplantation. , 2009, , 409-416.		3
718	CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells. <i>Clinical Cancer Research</i> , 2009, 15, 2739-2746.	3.2	63
719	Rituximab Treatment of Adult Patients with Steroid-Resistant Focal Segmental Glomerulosclerosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1317-1323.	2.2	109
720	Rituximab in Severe Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 579-587.	2.2	151

#	ARTICLE	IF	CITATIONS
721	IDECA-2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. <i>European Journal of Haematology</i> , 1999, 62, 76-82.	1.1	151
722	Monoclonal anti-CD20 antibodies: Mechanisms of action and monitoring of biological effects. <i>Joint Bone Spine</i> , 2009, 76, 458-463.	0.8	28
723	Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. <i>Clinical Immunology</i> , 2009, 130, 199-212.	1.4	56
724	Immunogenicity of rituximab in patients with severe pemphigus. <i>Clinical Immunology</i> , 2009, 132, 334-341.	1.4	90
725	Treatment of relapsing polychondritis with rituximab: A retrospective study of nine patients. <i>Arthritis and Rheumatism</i> , 2009, 61, 577-582.	6.7	67
726	Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1540-1547.	6.7	182
727	Rituximab may form a complex with IgM ⁺ mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus ⁺ induced vasculitis. <i>Arthritis and Rheumatism</i> , 2009, 60, 3848-3855.	6.7	129
728	Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma. <i>Investigational New Drugs</i> , 2009, 27, 476-481.	1.2	10
729	Targeted therapy for chronic lymphocytic leukemia. <i>Targeted Oncology</i> , 2009, 4, 11-21.	1.7	13
731	Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). <i>Annals of Hematology</i> , 2009, 88, 239-243.	0.8	15
732	Rituximab (B-cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature. <i>Pediatric Pulmonology</i> , 2009, 44, 922-934.	1.0	48
733	Rituximab in non-haematological disorders of adults and its mode of action. <i>British Journal of Haematology</i> , 2009, 146, 233-246.	1.2	47
734	Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 561-573.	1.1	19
735	Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2009, 43, 679-684.	1.3	18
736	Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients. <i>Leukemia Research</i> , 2009, 33, 792-797.	0.4	21
737	Mécanismes de l'action des anticorps monoclonaux anti-CD20 et surveillance biologique de leurs effets. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2009, 76, 826-832.	0.0	2
738	Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 233-242.	6.6	93
739	RGD Dendron Bodies; Synthetic Avidity Agents with Defined and Potentially Interchangeable Effector Sites That Can Substitute for Antibodies. <i>Bioconjugate Chemistry</i> , 2009, 20, 1853-1859.	1.8	36

#	ARTICLE	IF	CITATIONS
740	Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 498-503.	0.8	168
742	Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷ Lu-DOTATATE and ⁹⁰ Y-DOTATOC. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 659-665.	0.7	33
743	Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 181-193.	1.3	6
744	Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 514-516.	0.6	15
745	Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. <i>Leukemia and Lymphoma</i> , 2009, 50, 873-885.	0.6	49
746	Analisi di costo-efficacia di rituximab piA1 CHOP versus ProMACE-CytaBOM nel trattamento del linfoma diffuso a grandi cellule B: lâ™esperienza di Reggio Emilia. <i>Giornale Italiano Di Health Technology Assessment</i> , 2009, 2, 55-64.	0.1	0
747	Squamous Cell Carcinoma and Malignant Lymphoma as Synchronous Malignant Tumours in the Oral Cavity. <i>Asian Journal of Oral and Maxillofacial Surgery</i> , 2009, 21, 64-68.	0.1	2
748	Comparative Outcome Analysis of ABO-Incompatible and Positive Crossmatch Renal Transplantation: A Single-Center Experience. <i>Transplantation</i> , 2009, 87, 1889-1896.	0.5	28
749	Successful Use of Single-Dose Rituximab for the Maintenance of Remission in a Patient with Steroid-Resistant Nephrotic Syndrome. <i>Internal Medicine</i> , 2009, 48, 1901-1904.	0.3	27
750	VelocImmune: Immunoglobulin Variable Region Humanized Mice. , 0, , 100-108.		2
751	Phase 1/2 study of fractionated ¹³¹ I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. <i>Blood</i> , 2009, 113, 1412-1421.	0.6	79
752	Anti-idiotypic antibody response after vaccination correlates with better overall survival in follicular lymphoma. <i>Blood</i> , 2009, 113, 5743-5746.	0.6	49
755	Evaluation and Validation of Diagnostic Tests for Guiding Therapeutic Decisions. <i>Therapie</i> , 2009, 64, 195-201.	0.6	7
756	Reactive Oxygen Species, Cancer and Anti-Cancer Therapies. <i>Current Chemical Biology</i> , 2009, 3, 342-366.	0.2	138
757	Successful combination of Rituximab and plasma exchange in the treatment of cryoglobulinemic vasculitis with skin ulcers: a case report. <i>Cases Journal</i> , 2009, 2, 7859.	0.4	13
758	Front-line management of diffuse large B cell lymphoma. <i>Current Opinion in Oncology</i> , 2010, 22, 642-645.	1.1	27
759	Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2010, 5, 197-204.	0.8	9
760	Late-Onset Neutropenia After Rituximab Treatment. <i>Medicine (United States)</i> , 2010, 89, 308-318.	0.4	137

#	ARTICLE	IF	CITATIONS
762	Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. <i>Blood</i> , 2010, 115, 2755-2762.	0.6	242
763	Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2010, 115, 3008-3016.	0.6	254
764	Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. <i>Annals of Hematology</i> , 2010, 89, 283-289.	0.8	11
765	A general process for the development of peptide-based immunoassays for monoclonal antibodies. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 919-925.	1.1	16
766	Monoclonal antibodies – a proven and rapidly expanding therapeutic modality for human diseases. <i>Protein and Cell</i> , 2010, 1, 319-330.	4.8	52
767	Molecular Regulation of JC Virus Tropism: Insights into Potential Therapeutic Targets for Progressive Multifocal Leukoencephalopathy. <i>Journal of NeuroImmune Pharmacology</i> , 2010, 5, 404-417.	2.1	55
768	Developing macromolecular therapeutics: the future drug-of-choice. <i>Frontiers of Chemical Engineering in China</i> , 2010, 4, 10-17.	0.6	8
769	Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. <i>Investigational New Drugs</i> , 2010, 28, 561-574.	1.2	22
770	Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. <i>Journal of Immunological Methods</i> , 2010, 360, 30-38.	0.6	25
771	The yin and yang of B cells in graft rejection and tolerance. <i>Transplantation Reviews</i> , 2010, 24, 67-78.	1.2	51
772	Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 608.e1-608.e8.	0.7	19
773	B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. <i>Experimental Hematology</i> , 2010, 38, 213-221.	0.2	35
774	Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 805-817.	1.6	3
775	Clinical outcome of patients with follicular lymphoma and bulky disease after Rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy. <i>European Journal of Haematology</i> , 2010, 85, 11-19.	1.1	4
776	Low-dose rituximab in adult patients with primary immune thrombocytopenia. <i>European Journal of Haematology</i> , 2010, 85, 329-334.	1.1	108
777	Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naïve, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden. <i>Cancer</i> , 2010, 116, 4299-4308.	2.0	15
778	VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: A multicenter experience. <i>Archives of Gerontology and Geriatrics</i> , 2010, 51, 209-215.	1.4	7
779	A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia. <i>Leukemia</i> , 2010, 24, 1265-1275.	3.3	21

#	ARTICLE	IF	CITATIONS
780	Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. <i>Clinical Transplantation</i> , 2010, 24, 223-228.	0.8	56
781	Rituximab for the treatment of patients with chronic lymphocytic leukemia. <i>Cancer Management and Research</i> , 2010, 2, 71.	0.9	4
784	Management of non-Hodgkin's lymphoma in older adults. , 2010, , 274-287.		0
785	Role of rituximab in first-line treatment of chronic lymphocytic leukemia. <i>Therapeutics and Clinical Risk Management</i> , 2010, 7, 1.	0.9	8
786	Rituximab in severe skin diseases: target, disease, and dose. <i>Clinical Pharmacology: Advances and Applications</i> , 2010, 2, 135.	0.8	5
787	A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency. <i>OncoTargets and Therapy</i> , 2010, 3, 99.	1.0	4
788	Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. <i>Annals of Oncology</i> , 2010, 21, 1699-1705.	0.6	16
789	Utility of Influenza Vaccination for Oncology Patients. <i>Journal of Clinical Oncology</i> , 2010, 28, 2481-2490.	0.8	96
790	Wnt Inhibitor Dickkopf-1 as a Target for Passive Cancer Immunotherapy. <i>Cancer Research</i> , 2010, 70, 5326-5336.	0.4	131
791	Managing HBV in patients with impaired immunity. <i>Gut</i> , 2010, 59, 1430-1445.	6.1	63
792	Safety Assessment Considerations and Strategies for Targeted Small Molecule Cancer Therapeutics in Drug Discovery. <i>Toxicologic Pathology</i> , 2010, 38, 165-168.	0.9	19
793	Investigations of bio markers for human lymphoblastoid cells using Atomic Force Microscopy. , 2010, , .		1
794	Ultra-compliant thermal AFM probes for studying of cellular properties. , 2010, , .		3
795	Immunomodulatory drug treatment in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1423-1436.	1.4	11
796	Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. <i>Blood</i> , 2010, 116, 335-342.	0.6	112
797	B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12747-12754.	3.3	143
798	Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 732-737.	3.3	54
799	Therapeutic monoclonal antibody concentration monitoring: free or total?. <i>Bioanalysis</i> , 2010, 2, 1125-1140.	0.6	86

#	ARTICLE	IF	CITATIONS
800	Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-14.	3.3	20
801	Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials. <i>Journal of Rheumatology</i> , 2010, 37, 558-567.	1.0	265
802	Novel ways to attack inflammation in thyroid eye disease. <i>Expert Review of Ophthalmology</i> , 2010, 5, 277-281.	0.3	1
803	Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies. <i>Current Drug Targets</i> , 2010, 11, 790-800.	1.0	10
804	Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly. <i>Current Pharmaceutical Design</i> , 2010, 16, 2872-2879.	0.9	6
805	Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. <i>Annals of Oncology</i> , 2010, 21, 1217-1221.	0.6	22
806	An Improved Bicistronic CD20/tCD34 Vector for Efficient Purification and In Vivo Depletion of Gene-Modified T Cells for Adoptive Immunotherapy. <i>Molecular Therapy</i> , 2010, 18, 1330-1338.	3.7	60
807	Innovative Uses of Rituximab in Dermatology. <i>Dermatologic Clinics</i> , 2010, 28, 547-557.	1.0	19
808	Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2010, 95, 329-332.	1.7	44
809	Rituximab. <i>Drugs</i> , 2010, 70, 1445-1476.	4.9	163
810	Role of CD20 Monoclonal Antibodies in Previously Untreated Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, S27-S33.	0.2	3
811	Infusion Reactions. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, E10-E21.	0.3	165
812	Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies. <i>BioDrugs</i> , 2010, 24, 23-39.	2.2	173
813	The ability of human bispecific anti-idiotypic antibody to elicit humoral and cellular immune responses in mice. <i>International Immunopharmacology</i> , 2010, 10, 707-712.	1.7	3
814	Monoclonal antibody therapy of chronic lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 133-143.	0.7	16
815	Therapy of MS. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 365-385.	0.6	85
816	Experience with maintenance rituximab after chemotherapy in patients with low-grade lymphoma. <i>Community Oncology</i> , 2010, 7, 414-417.	0.2	1
817	Rituximab in Chronic Lymphocytic Leukemia. <i>Seminars in Hematology</i> , 2010, 47, 156-169.	1.8	41

#	ARTICLE	IF	CITATIONS
818	Rituximab-Associated Neutropenia. <i>Seminars in Hematology</i> , 2010, 47, 180-186.	1.8	80
819	Rituximab: Mechanism of Action. <i>Seminars in Hematology</i> , 2010, 47, 115-123.	1.8	629
820	Dose Intensified Molecular Targeted Radiotherapy for Cancerâ€™Lymphoma as a Paradigm. <i>Seminars in Nuclear Medicine</i> , 2010, 40, 136-144.	2.5	7
821	Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR. <i>Journal of Immunology</i> , 2010, 184, 1968-1976.	0.4	324
822	Autologous transplant of follicular lymphoma in the era of rituximab. <i>Leukemia and Lymphoma</i> , 2010, 51, 967-974.	0.6	11
823	The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoproliferative neoplastic disorders. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 551-557.	1.4	8
824	Treatment of Mucosa-associated Lymphoid Tissue Lymphoma in Sjögrenâ€™s Syndrome: A Retrospective Clinical Study. <i>Journal of Rheumatology</i> , 2011, 38, 2198-2208.	1.0	78
825	Cytokine therapy: clinical and progressive status in cancer. <i>International Journal of Immunological Studies</i> , 2011, 1, 264.	0.2	0
826	The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF- κ B/Snail/RKIP/PTEN resistance loop in B-NHL cells: Role in sensitization to TRAIL apoptosis. <i>International Journal of Oncology</i> , 2011, 38, 1683-94.	1.4	25
827	Effect of Single-Dose Rituximab on Primary Glomerular Diseases. <i>Nephron Clinical Practice</i> , 2011, 117, c98-c105.	2.3	54
828	Principles of Anticancer Drug Development. , 2011, , .		0
829	Cancer Immunotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 1-64.	0.7	120
832	Biotherapeutic bioanalysis: a multi-indication case study review. <i>Bioanalysis</i> , 2011, 3, 623-643.	0.6	20
833	Rituximab resistance. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 203-216.	0.7	189
834	Molecular engineering to improve antibodiesâ€™ anti-lymphoma activity. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 217-229.	0.7	18
835	Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management. <i>Saudi Journal of Ophthalmology</i> , 2011, 25, 15-20.	0.3	6
836	Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. <i>Transplant Immunology</i> , 2011, 24, 142-148.	0.6	16
837	Radiolabeling of rituximab with ¹⁸⁸ Re and ^{99m} Tc using the tricarbonyl technology. <i>Nuclear Medicine and Biology</i> , 2011, 38, 19-28.	0.3	29

#	ARTICLE	IF	CITATIONS
838	The pharmacokinetics of ¹³¹ I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab. Human Antibodies, 2011, 20, 37-40.	0.6	2
839	IMMUNOMODULATORS AND THE "BIOLOGICS" IN CUTANEOUS EMERGENCIES. , 0, , 34-49.		0
840	Acquired hemophilia A. Advances in Clinical Chemistry, 2011, 54, 71-80.	1.8	16
841	CD20 antigen imaging with ¹²⁴ I-rituximab PET/CT in patients with rheumatoid arthritis. Human Antibodies, 2011, 20, 29-35.	0.6	28
842	Neutropenia associated with rituximab therapy. Current Opinion in Hematology, 2011, 18, 49-54.	1.2	31
843	Evaluation of Current Cancer Immunotherapy. Cancer Journal (Sudbury, Mass), 2011, 17, 309-324.	1.0	18
844	Herpesviridae Viral Infections following Rituximab Combined Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma. Acta Haematologica, 2011, 125, 230-236.	0.7	5
845	The 5-Year Outcome of ABO-Incompatible Kidney Transplantation With Rituximab Induction. Transplantation, 2011, 91, 853-857.	0.5	114
847	Current and Future Therapeutic Targets of Rheumatoid Arthritis. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2011, 10, .	1.1	5
848	Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines. Oncology Reports, 2011, 26, 637-44.	1.2	6
849	CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood, 2011, 117, 2423-2432.	0.6	195
850	Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood, 2011, 118, 6769-6771.	0.6	145
851	Transition of thyroid autoantibodies by rituximab treatment for thyroid MALT lymphoma. Endocrine Journal, 2011, 58, 7-12.	0.7	12
852	BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties. International Journal of Oncology, 2011, 38, 335-44.	1.4	45
853	Desensitization for renal transplantation: depletion of donor-specific anti-HLA antibodies, preservation of memory antibodies, and clinical risks. Transplant International, 2011, 24, 21-29.	0.8	17
854	Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: A pilot study. Cancer Science, 2011, 102, 1565-1567.	1.7	22
855	Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study. Cancer Science, 2011, 102, 1698-1705.	1.7	21
856	Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies. Immunology, 2011, 133, 239-245.	2.0	32

#	ARTICLE	IF	CITATIONS
857	A standardized conversion of IgG antibody to bispecific form with inversely altered affinities for Fcγ ₃ -receptors II and III. <i>Molecular Immunology</i> , 2011, 48, 760-768.	1.0	4
858	Immunology and immunotherapy of neuroblastoma. <i>Seminars in Cancer Biology</i> , 2011, 21, 229-237.	4.3	69
859	B-cell therapies in established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 535-548.	1.4	34
860	Suppression of neuro inflammation in experimental autoimmune encephalomyelitis by glia maturation factor antibody. <i>Brain Research</i> , 2011, 1373, 230-239.	1.1	18
861	An Fcγ ₃ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells. <i>Cancer Cell</i> , 2011, 19, 101-113.	7.7	247
862	Autoimmune phenomena in untreated and treated marginal zone lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2369-2379.	0.9	7
863	Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. <i>American Journal of Hematology</i> , 2011, 86, 278-291.	2.0	21
864	Biopharmaceuticals and monoclonal antibodies in oncology trials—a cross-sectional analysis. <i>Protein Engineering, Design and Selection</i> , 2011, 24, 105-111.	1.0	6
865	Developmental Immunotoxicology Assessment of Rituximab in Cynomolgus Monkeys. <i>Toxicological Sciences</i> , 2011, 119, 116-125.	1.4	60
866	Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy. <i>Mini-Reviews in Medicinal Chemistry</i> , 2011, 11, 611-624.	1.1	15
867	Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. <i>Haematologica</i> , 2011, 96, 307-314.	1.7	113
868	Spotlight on Rituximab in Chronic Lymphocytic Leukemia, Low-Grade or Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma. <i>BioDrugs</i> , 2011, 25, 55-61.	2.2	11
869	Republished paper: Managing HBV in patients with impaired immunity. <i>Postgraduate Medical Journal</i> , 2011, 87, 223-238.	0.9	3
870	Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus—a prospective pilot study. <i>Rheumatology</i> , 2011, 50, 1640-1644.	0.9	50
871	The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S4087.	0.6	8
872	Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3990-3998.	0.8	59
873	Development and testing of nano robot end effector for cell electrophysiology and elastography studies. , 2011, , .		1
875	Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1333-1340.	1.1	13

#	ARTICLE	IF	CITATIONS
876	Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 529-541.	1.3	41
877	<i>Ex Vivo</i> Graft Purging and Expansion of Autologous Blood Progenitor Cell Products from Patients with Multiple Myeloma. <i>Cancer Research</i> , 2011, 71, 5040-5049.	0.4	14
878	Monoclonal antibodies in hematological malignancies: Past, present and future. <i>Journal of Cancer Research and Therapeutics</i> , 2011, 7, 399.	0.3	16
879	New Treatment Alternatives in the Management of Non-Infectious Intraocular Inflammations: Biologic Agents. <i>Türk Oftalmoloji Dergisi</i> , 2011, 41, 243-255.	0.4	0
880	Therapy of newly diagnosed follicular lymphoma. <i>Frontiers in Oncology</i> , 2012, 2, 188.	1.3	0
881	Successful Treatment of Cryoglobulinaemia with Rituximab. <i>Case Reports in Nephrology and Urology</i> , 2012, 2, 72-77.	1.5	3
882	Incidence of Non-Neutropenic Infection (NNI) in Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma: The Effects of Rituximab Therapy. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2012, 22, 220-226.	0.1	0
883	Molecular radiotherapy. <i>Clinical Medicine</i> , 2012, 12, 381-386.	0.8	6
884	Rituximab and Multiple Sclerosis. <i>Clinical Neuropharmacology</i> , 2012, 35, 90-96.	0.2	12
885	Rituximab in anti-glomerular basement membrane disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 195-197.	0.2	35
886	The Role of Rituximab in the Therapy of Mixed Cryoglobulinemia. , 2012, , 297-305.		0
887	Monoclonal Antibodies as Cancer Therapeutics. <i>Recent Patents on Biotechnology</i> , 2012, 6, 45-56.	0.4	6
888	Galactosylation variations in marketed therapeutic antibodies. <i>MAbs</i> , 2012, 4, 385-391.	2.6	103
889	Possibility to Partly Win the War Against Cancer. , 2012, , 617-671.		3
890	Pharmacotherapy for adult acute lymphoblastic leukemia: an update from recent clinical trials and future directions. <i>Clinical Investigation</i> , 2012, 2, 715-731.	0.0	2
891	Combinatorial Chemotherapeutic Efficacy in Non-Hodgkin Lymphoma Can Be Predicted by a Signaling Model of CD20 Pharmacodynamics. <i>Cancer Research</i> , 2012, 72, 1632-1641.	0.4	30
892	Follicular lymphoma and the immune system: from pathogenesis to antibody therapy. <i>Blood</i> , 2012, 119, 3659-3667.	0.6	31
893	Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 552-560.	0.7	13

#	ARTICLE	IF	CITATIONS
894	Long-term safety of rituximab in patients with rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 383-390.	0.3	8
895	Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 199-207.	1.1	7
896	Diagnosis and treatment of diffuse large B-cell lymphoma. <i>Swiss Medical Weekly</i> , 2012, 142, w13511.	0.8	27
897	The evaluation and optimal use of rituximab in lymphoid malignancies. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, , 1.	1.2	2
898	Sjögren's Syndrome. , 2012, , .		9
899	Cancer Targeting Gene "Viro" Therapy and its Promising Future. , 2012, , 33-83.		5
900	Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 417-420.	0.5	0
901	Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan. <i>Medical Radiology</i> , 2012, , 551-556.	0.0	1
902	Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. <i>Haematologica</i> , 2012, 97, 1431-1438.	1.7	96
903	Current Issues in Vaccines for Adult Patients With Hematologic Malignancies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1447-1454.	2.3	13
904	The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. <i>Blood</i> , 2012, 119, 3276-3284.	0.6	218
905	Rituximab Treatment for Adult Patients with Focal Segmental Glomerulosclerosis. <i>Internal Medicine</i> , 2012, 51, 759-762.	0.3	26
906	Rituximab: emerging treatment strategies of immune-mediated glomerular disease. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 413-421.	1.3	10
907	Targeted drug delivery for cancer therapy: the other side of antibodies. <i>Journal of Hematology and Oncology</i> , 2012, 5, 70.	6.9	232
908	Management of indolent lymphoma: Where are we now and where are we going. <i>Blood Reviews</i> , 2012, 26, 279-288.	2.8	43
909	Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling. <i>Cancer Science</i> , 2012, 103, 350-359.	1.7	2
910	Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma. <i>American Journal of Hematology</i> , 2012, 87, E68-71.	2.0	1
911	In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1211-1220.	2.0	16

#	ARTICLE	IF	CITATIONS
912	Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients. <i>Journal of Immunology</i> , 2012, 188, 3532-3541.	0.4	109
913	The Use of Monoclonal Antibodies in Immune-Mediated Hematologic Disorders. <i>Medical Clinics of North America</i> , 2012, 96, 583-619.	1.1	4
914	Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials. <i>Leukemia and Lymphoma</i> , 2012, 53, 77-82.	0.6	24
915	Application of the systematic review and bibliometric network analysis (SeBriNA) methodology contextualizes evidence. Part 2: rituximab for non-Hodgkin's lymphoma. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 996-1009.	2.4	6
916	Rituximab. <i>BioDrugs</i> , 2012, 26, 71-82.	2.2	15
917	Role of randomized phase III trials in an era of effective targeted therapies. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 208-214.	12.5	46
918	Hybridoma Technology for the Generation of Monoclonal Antibodies. <i>Methods in Molecular Biology</i> , 2012, 901, 117-135.	0.4	82
919	Expression of CD20 reveals a new store-operated calcium entry modulator in skeletal muscle. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 2095-2105.	1.2	9
920	Radiolabeled Antibodies for Cancer Imaging and Therapy. <i>Methods in Molecular Biology</i> , 2012, 907, 681-697.	0.4	61
921	To B or Not to B the Conductor of Rheumatoid Arthritis Orchestra. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 43, 281-291.	2.9	42
922	Antibody Engineering. <i>Methods in Molecular Biology</i> , 2012, , .	0.4	9
923	Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. <i>Annals of Hematology</i> , 2012, 91, 715-721.	0.8	20
924	Anti-CD20 Antibody Therapy for B-Cell Lymphomas. <i>New England Journal of Medicine</i> , 2012, 366, 2008-2016.	13.9	264
925	Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation. <i>Hematological Oncology</i> , 2012, 30, 143-149.	0.8	29
926	Using antibodies to target cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1173-1190.	1.4	19
927	Two Hundred Years of Cancer Research. <i>New England Journal of Medicine</i> , 2012, 366, 2207-2214.	13.9	228
928	Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. <i>Annals of Hematology</i> , 2012, 91, 1007-1012.	0.8	80
929	Low-dose rituximab is effective in pemphigus. <i>British Journal of Dermatology</i> , 2012, 166, 405-412.	1.4	89

#	ARTICLE	IF	CITATIONS
930	Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of Fc γ RIIB receptors. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012, 1823, 505-513.	1.9	12
931	Novel roles for the IgG Fc glycan. <i>Annals of the New York Academy of Sciences</i> , 2012, 1253, 170-180.	1.8	160
932	Excellent Outcomes of ABO-Incompatible Kidney Transplantation: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2012, 44, 204-209.	0.3	31
933	Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 597-605.	1.1	20
934	Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry. <i>Annals of Hematology</i> , 2012, 91, 561-570.	0.8	11
935	Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. <i>Clinical Rheumatology</i> , 2013, 32, 79-82.	1.0	29
936	Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. <i>Journal of Translational Medicine</i> , 2013, 11, 160.	1.8	31
937	Resistance to Immunotherapeutic Antibodies in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , .	0.1	2
938	Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma. <i>Cancer Cell International</i> , 2013, 13, 58.	1.8	12
939	Targeted immunotherapy trials for idiopathic inflammatory myopathies. <i>Journal of Neurology</i> , 2013, 260, 368-385.	1.8	1
940	Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1251-1255.	1.2	41
941	Indications for use and safety of rituximab in childhood renal diseases. <i>Pediatric Nephrology</i> , 2013, 28, 1001-1009.	0.9	11
942	Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma. <i>Supportive Care in Cancer</i> , 2013, 21, 1145-1152.	1.0	18
943	Rituximab pharmacokinetics in children and adolescents with <i>de novo</i> intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. <i>British Journal of Haematology</i> , 2013, 162, 678-683.	1.2	31
944	Immunotherapy strategies for multiple myeloma: the present and the future. <i>Immunotherapy</i> , 2013, 5, 1005-1020.	1.0	4
945	Targeting developmental pathways in children with cancer: what price success?. <i>Lancet Oncology</i> , 2013, 14, e70-e78.	5.1	30
946	Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 471-478.	0.4	18
947	Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patients. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 404-411.	0.6	90

#	ARTICLE	IF	CITATIONS
948	Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies. <i>Cancer Treatment Reviews</i> , 2013, 39, 632-639.	3.4	63
949	Heterophilic antibody interference in immunometric assays. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2013, 27, 647-661.	2.2	165
950	Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. <i>Kidney International</i> , 2013, 83, 511-516.	2.6	115
951	Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1225-1232.	0.4	66
952	Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. <i>Clinical Rheumatology</i> , 2013, 32, 695-700.	1.0	61
953	Real Time Analysis of Binding between Rituximab (Anti-CD20 Antibody) and B Lymphoma Cells. <i>Analytical Chemistry</i> , 2013, 85, 8543-8551.	3.2	25
954	Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 169-182.	1.4	21
955	Progressive Multifocal Leukoencephalopathy in a Heart Transplant Recipient Following Rituximab Therapy for Antibody-Mediated Rejection. <i>American Journal of Transplantation</i> , 2013, 13, 1075-1079.	2.6	14
956	Treating chemotherapy induced agranulocytosis with granulocyte colony-stimulating factors in a patient on clozapine. <i>Psycho-Oncology</i> , 2013, 22, 1674-1675.	1.0	16
957	Treatment approaches to asymptomatic follicular lymphoma. <i>Expert Review of Hematology</i> , 2013, 6, 747-758.	1.0	0
958	Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 106-111.	0.2	246
959	New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D82-D91.	1.2	113
960	Rituximab in dermatology. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 380-392.	0.2	6
961	Rituximab en dermatología. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 380-392.	0.2	9
962	CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 925-933.	2.0	35
963	A review of the use of biological agents for chronic inflammatory demyelinating polyradiculoneuropathy. <i>Journal of the Neurological Sciences</i> , 2013, 326, 1-9.	0.3	10
964	Monoclonal Antibodies in Conditioning Regimens for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1288-1300.	2.0	11
965	Monoclonal antibodies based on hybridoma technology. <i>Pharmaceutical Patent Analyst</i> , 2013, 2, 249-263.	0.4	20

#	ARTICLE	IF	CITATIONS
966	Engineered SIRP± Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies. <i>Science</i> , 2013, 341, 88-91.	6.0	401
967	The first antibody therapy for cancer: a personal experience. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 399-406.	1.1	2
968	B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid. <i>American Journal of Gastroenterology</i> , 2013, 108, 933-941.	0.2	102
969	Immune and Inflammatory Role in Renal Disease. , 2013, 3, 957-976.		254
970	Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions. <i>Current Molecular Medicine</i> , 2013, 13, 165-178.	0.6	13
971	PharmacocinÃ©tique des anticorps monoclonaux. , 2013, , 275-285.		0
972	Rituximab for the treatment of follicular lymphoma. <i>Future Oncology</i> , 2013, 9, 1283-1298.	1.1	3
973	Selective Activation of Antigen-Experienced T Cells by Anti-CD3 Constrained on Nanoparticles. <i>Journal of Immunology</i> , 2013, 191, 5107-5114.	0.4	18
975	Integration of Different "omics" Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of Shikonin against Leukemia Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-11.	0.5	24
976	Currently available and potential future treatment options for IgA nephropathy. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 625-635.	0.5	0
977	Antibody Glycosylation and Inflammation. <i>Antibodies</i> , 2013, 2, 392-414.	1.2	94
978	Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients. <i>Rheumatology</i> , 2013, 52, 1462-1466.	0.9	3
979	Modulation of Tumor Immunity by Soluble and Membrane-Bound Molecules at the Immunological Synapse. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-19.	3.3	12
980	Identification of human leucocyte antigen (HLA)A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DO ² as a novel target for multiple myeloma. <i>British Journal of Haematology</i> , 2013, 163, 343-351.	1.2	15
981	Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. <i>Journal of Clinical Oncology</i> , 2013, 31, 573-583.	0.8	142
982	Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. <i>Blood</i> , 2013, 121, 4694-4702.	0.6	79
983	The role of monoclonal antibodies in the treatment of lymphomas. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 227-239.	1.4	4
984	Follow-up Data of 10 Patients With B-cell Non-Hodgkin Lymphoma With a CD20-negative Phenotypic Change After Rituximab-containing Therapy. <i>American Journal of Surgical Pathology</i> , 2013, 37, 563-570.	2.1	20

#	ARTICLE	IF	CITATIONS
985	Rituximab Treatment for Adult Purpura Nephritis with Nephrotic Syndrome. <i>Internal Medicine</i> , 2013, 52, 1079-1083.	0.3	17
986	Hepatitis B virus reactivation with rituximab-containing regimen. <i>World Journal of Hepatology</i> , 2013, 5, 612.	0.8	27
987	Comparability of a Three-Dimensional Structure in Biopharmaceuticals Using Spectroscopic Methods. <i>Journal of Analytical Methods in Chemistry</i> , 2014, 2014, 1-11.	0.7	5
988	Animal models and therapeutic molecular targets of cancer: utility and limitations. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1911.	2.0	196
989	Developing T Cell Cancer Immunotherapy in the Dog with Lymphoma. <i>ILAR Journal</i> , 2014, 55, 169-181.	1.8	17
990	Gene therapy for cancer: present status and future perspective. <i>Molecular and Cellular Therapies</i> , 2014, 2, 27.	0.2	185
991	Targeting cholesterol synthesis increases chemoimmuno-sensitivity in chronic lymphocytic leukemia cells. <i>Experimental Hematology and Oncology</i> , 2014, 3, 24.	2.0	17
992	In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 1923-1937.	2.4	27
993	Using a Single Parameter to Describe Time-Activity Curves. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 83-86.	0.7	0
994	Rituximab: modes of action, remaining dispute and future perspective. <i>Future Oncology</i> , 2014, 10, 2481-2492.	1.1	41
995	Use of rituximab as a treatment for systemic lupus erythematosus: retrospective review. <i>Einstein (Sao) Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	0.5	10
996	Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study. <i>Bone Marrow Transplantation</i> , 2014, 49, 73-79.	1.3	25
997	Neurologic Complications of Chemotherapy and Radiation Therapy. , 2014, , 591-609.		2
998	Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 311-326.	1.4	13
999	Rituximab for Non-Hodgkin's Lymphoma: A Story of Rapid Success in Translation. <i>Clinical and Translational Science</i> , 2014, 7, 82-86.	1.5	28
1000	Chronic Lymphocytic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2265.	3.8	134
1001	Fc γ 3 Receptors as Therapeutic Targets. , 2014, , 283-296.		1
1002	Oncogene withdrawal engages the immune system to induce sustained cancer regression. , 2014, 2, 24.		19

#	ARTICLE	IF	CITATIONS
1003	A Systematic Review of the Use of Rituximab for Desensitization in Renal Transplantation. <i>Transplantation</i> , 2014, 98, 794-805.	0.5	51
1004	Prolonged B Cell Depletion With Rituximab is Effective in Treating Refractory Pulmonary Granulomatous Inflammation in Granulomatosis With Polyangiitis (GPA). <i>Medicine (United States)</i> , 2014, 93, e229.	0.4	12
1005	Rituximab Therapy for Refractory Orbital Inflammation. <i>JAMA Ophthalmology</i> , 2014, 132, 572.	1.4	59
1006	Monoclonal antibodies for the prevention of rabies: theory and clinical practice. <i>Antibody Technology Journal</i> , 0, , 1.	0.0	15
1007	Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2014, , 45.	1.2	0
1008	Three major uncertainties in the antibody therapy of cancer. <i>Haematologica</i> , 2014, 99, 1538-1546.	1.7	18
1009	Antibodyâ€“Drug Conjugates: An Emerging Concept in Cancer Therapy. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 3796-3827.	7.2	779
1010	An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. <i>Immunologic Research</i> , 2014, 58, 282-291.	1.3	18
1011	A multiâ€“centre, singleâ€“arm, openâ€“label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (Râ€“scp>ITP</scp>1000 study). <i>British Journal of Haematology</i> , 2014, 167, 243-251.	1.2	27
1012	Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. <i>Neurology</i> , 2014, 83, 142-150.	1.5	275
1014	Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance. <i>Seminars in Oncology</i> , 2014, 41, 667-677.	0.8	43
1015	Monoclonal antibodies in treatment of multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2014, 175, 373-384.	1.1	56
1016	Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma. <i>Journal of Immunology</i> , 2014, 193, 1519-1524.	0.4	46
1017	CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells. <i>Cancer Immunology Research</i> , 2014, 2, 878-889.	1.6	48
1018	A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. <i>Clinical Immunology</i> , 2014, 154, 37-46.	1.4	25
1019	A drug safety evaluation of rituximab and risk of hepatitis B. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 977-987.	1.0	16
1020	Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?. <i>Clinical Cancer Research</i> , 2014, 20, 5226-5239.	3.2	17
1021	Monoclonal antibodies as therapeutics in human malignancies. <i>Future Oncology</i> , 2014, 10, 609-636.	1.1	20

#	ARTICLE	IF	CITATIONS
1022	Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Medical Oncology</i> , 2014, 31, 56.	1.2	12
1023	Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy. <i>Survey of Ophthalmology</i> , 2014, 59, 493-502.	1.7	29
1024	Anti-CD79 Antibody Induces B Cell Anergy That Protects against Autoimmunity. <i>Journal of Immunology</i> , 2014, 192, 1641-1650.	0.4	35
1025	Immediate infusional reactions to intravenous immunobiological agents for the treatment of autoimmune diseases: experience of 2126 procedures in a non-oncologic infusion centre. <i>Revista Brasileira De Reumatologia</i> , 2014, 54, 102-109.	0.7	6
1026	Variability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy?. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 279-293.	0.3	7
1028	Long-Term Prognosis of Adult Patients with Steroid-Dependent Minimal Change Nephrotic Syndrome Following Rituximab Treatment. <i>Medicine (United States)</i> , 2014, 93, e300.	0.4	36
1030	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. <i>Blood</i> , 2015, 125, 82-89.	0.6	45
1031	Patient-derived heavy chain antibody targets cell surface HSP90 on breast tumors. <i>BMC Cancer</i> , 2015, 15, 614.	1.1	17
1032	Radiolabelling rituximab with ^{99m} Tc in three steps procedure. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 274-280.	0.5	5
1033	Fludarabine in the Treatment of Refractory Chronic Inflammatory Demyelinating Neuropathies. <i>Journal of Clinical Neuromuscular Disease</i> , 2015, 17, 1-5.	0.3	8
1034	Neurologic Complications of Chemotherapy and Radiation Therapy. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2015, 21, 429-451.	0.4	15
1035	The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 351-356.	1.0	2
1036	Artificial Antigen Presenting Cells: An Off the Shelf Approach for Generation of Desirable T-Cell Populations for Broad Application of Adoptive Immunotherapy. <i>Advancements in Genetic Engineering</i> , 2015, 04, .	0.1	12
1037	Hepatitis B virus reactivation with a rituximab-containing regimen. <i>World Journal of Hepatology</i> , 2015, 7, 2344.	0.8	63
1039	Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics. <i>Frontiers in Immunology</i> , 2015, 6, 424.	2.2	12
1040	A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. <i>PLoS ONE</i> , 2015, 10, e0144712.	1.1	39
1041	Targeted Therapies in Adult B-Cell Malignancies. <i>BioMed Research International</i> , 2015, 2015, 1-16.	0.9	12
1042	Harnessing the Microbiome to Enhance Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2015, 2015, 1-12.	0.9	54

#	ARTICLE	IF	CITATIONS
1044	A mild form of rituximab-associated lung injury in two adolescents treated for nephrotic syndrome: Table 1. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212694.	0.2	6
1045	Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3113-3120.	3.2	109
1046	Recent advances in the field of anti-cancer immunotherapy. <i>BBA Clinical</i> , 2015, 3, 280-288.	4.1	72
1047	A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. <i>Theranostics</i> , 2015, 5, 834-846.	4.6	41
1048	Building better monoclonal antibody-based therapeutics. <i>Nature Reviews Cancer</i> , 2015, 15, 361-370.	12.8	558
1049	Biopharmaceutical Products from Animal Cell Culture. <i>Cell Engineering</i> , 2015, , 717-757.	0.4	11
1050	Anti-CD20 therapy induces a memory Th1 response through the IFN- γ /IL-12 axis and prevents protumor regulatory T-cell expansion in mice. <i>Leukemia</i> , 2015, 29, 947-957.	3.3	45
1051	Monoclonal antibodies: Pharmacokinetics as a basis for new dosage regimens?. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 370-376.	0.5	6
1052	Drug-free macromolecular therapeutics – a new paradigm in polymeric nanomedicines. <i>Biomaterials Science</i> , 2015, 3, 908-922.	2.6	50
1053	In situ production of therapeutic monoclonal antibodies. <i>Expert Review of Vaccines</i> , 2015, 14, 205-219.	2.0	9
1054	A systematic review of the use of rituximab as induction therapy in renal transplantation. <i>Transplantation Reviews</i> , 2015, 29, 103-108.	1.2	20
1055	Recent advances in targeted nanoparticles drug delivery to melanoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 769-794.	1.7	94
1056	The double-edged sword: Neurotoxicity of chemotherapy. <i>Blood Reviews</i> , 2015, 29, 93-100.	2.8	117
1057	CD20-positive primary gastric T-cell lymphoma poorly responding to initial treatment with rituximab plus CHOP, and a literature review. <i>International Journal of Hematology</i> , 2015, 102, 702-708.	0.7	17
1058	Large granular lymphocyte leukemia: clinical background, molecular pathogenesis and treatment. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 859-867.	0.5	0
1059	Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. , 2015, , 135-183.		0
1060	The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 791-808.	2.5	7
1061	Genetics and novel aspects of therapies in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2015, 14, 1005-1018.	2.5	72

#	ARTICLE	IF	CITATIONS
1062	Cancer Immunotherapy Confers a Global Benefit. , 2015, , 1-39.		0
1063	A pretargeting system for tumor PET imaging and radioimmunotherapy. <i>Frontiers in Pharmacology</i> , 2015, 6, 54.	1.6	41
1064	Absolute and multiplex quantification of antibodies in serum using PSAQâ„¢ standards and LC-MS/MS. <i>Bioanalysis</i> , 2015, 7, 1237-1251.	0.6	18
1065	Anti-CD20 single chain variable antibody fragmentâ€™apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas. <i>Biochemistry and Cell Biology</i> , 2015, 93, 343-350.	0.9	14
1066	How to Reduce Lethal Infectious Complications in ABO-Incompatible Kidney Transplantation. <i>Transplantation Proceedings</i> , 2015, 47, 653-659.	0.3	11
1067	Historical trends of radiotherapy use in prevalent malignancies over 38Âˆyears in SEER. <i>Journal of Radiation Oncology</i> , 2015, 4, 11-17.	0.7	3
1068	Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus. <i>Immunotherapy</i> , 2015, 7, 255-270.	1.0	6
1069	Prodrug Conjugate Strategies in Targeted Anticancer Drug Delivery Systems. <i>Advances in Delivery Science and Technology</i> , 2015, , 367-387.	0.4	1
1070	Hypersensitivity to Biological Agentsâ€™Updated Diagnosis, Management, and Treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 175-185.	2.0	87
1071	A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. <i>Future Oncology</i> , 2015, 11, 1327-1342.	1.1	61
1072	Multifunctional nanoparticles for use in theranostic applications. <i>Drug Delivery and Translational Research</i> , 2015, 5, 295-309.	3.0	85
1073	Multifunctional receptor-targeting antibodies for cancer therapy. <i>Lancet Oncology</i> , The, 2015, 16, e543-e554.	5.1	36
1074	Trends in excess mortality in follicular lymphoma at a population level. <i>European Journal of Haematology</i> , 2015, 94, 120-129.	1.1	11
1075	Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1337-1349.	1.1	5
1076	Are BiTEs the â€™missing linkâ€™ in cancer therapy?. <i>Oncolmmunology</i> , 2015, 4, e1008339.	2.1	59
1077	Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. <i>Oncolmmunology</i> , 2015, 4, e979688.	2.1	34
1078	Cancer targeted therapeutics: From molecules to drug delivery vehicles. <i>Journal of Controlled Release</i> , 2015, 219, 632-643.	4.8	89
1079	Donor- and recipient-derived immunity in ABO incompatible living-related liver transplantation. <i>Human Immunology</i> , 2015, 76, 631-635.	1.2	3

#	ARTICLE	IF	CITATIONS
1080	Novel immunotherapies for hematologic malignancies. <i>Immunological Reviews</i> , 2015, 263, 90-105.	2.8	44
1081	A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1878-1880.	0.6	4
1082	Targeting myeloid cells using nanoparticles to improve cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2015, 91, 38-51.	6.6	55
1083	Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. <i>Leukemia and Lymphoma</i> , 2015, 56, 1611-1618.	0.6	9
1084	The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma. <i>Targeted Oncology</i> , 2015, 10, 15-26.	1.7	18
1085	Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid. <i>Head and Neck</i> , 2016, 38, 410-416.	0.9	14
1086	Translational Medicine Case Studies and Reports. , 2016, , 135-156.		0
1087	Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. <i>Toxins</i> , 2016, 8, 274.	1.5	19
1088	Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2016, 56, 89-99.	0.3	36
1089	Establishment of anti-mesothelioma monoclonal antibodies. <i>BMC Research Notes</i> , 2016, 9, 324.	0.6	2
1090	War-winning weapons. <i>Nature Immunology</i> , 2016, 17, S18-S18.	7.0	0
1091	Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 197-208.	0.7	6
1092	Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. <i>British Journal of Haematology</i> , 2016, 175, 55-65.	1.2	12
1093	Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis. <i>Pediatrics International</i> , 2016, 58, 219-223.	0.2	14
1094	Cardiac non-Hodgkin's lymphoma: clinical characteristics and trends in survival. <i>European Journal of Haematology</i> , 2016, 97, 445-452.	1.1	55
1095	Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 597-616.	1.2	16
1096	Is rituximab suboptimally dosed in indolent B cell lymphoma?. <i>British Journal of Haematology</i> , 2016, 174, 721-729.	1.2	7
1097	Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after Rituximab: A population-based analysis. <i>Radiotherapy and Oncology</i> , 2016, 120, 150-155.	0.3	9

#	ARTICLE	IF	CITATIONS
1098	Rituximab-induced Acute Thrombocytopenia in High Tumor Burden Follicular Lymphoma. <i>Internal Medicine</i> , 2016, 55, 2061-2064.	0.3	11
1099	Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Deliveringâ€”A Cross-Sectional Analysis. <i>Oncologist</i> , 2016, 21, 487-493.	1.9	20
1100	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 1269-1280.	0.6	4
1101	Antibody-Based Treatment of Acute Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 545-552.	1.2	15
1102	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of antiâ€”cancer antibodies: IUPHAR Review 18. <i>British Journal of Pharmacology</i> , 2016, 173, 1407-1424.	2.7	56
1103	Anti-CD20 antibody treatment of non-Hodgkin lymphomas. <i>Clinical Immunology</i> , 2016, 172, 101-104.	1.4	21
1104	Improvement of a liposomal formulation with a native molecule: calcitriol. <i>RSC Advances</i> , 2016, 6, 80158-80167.	1.7	3
1105	Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2. <i>Cancer Gene Therapy</i> , 2016, 23, 341-347.	2.2	18
1106	Phage display-derived human antibodies in clinical development and therapy. <i>MAbs</i> , 2016, 8, 1177-1194.	2.6	263
1107	<i>Cancer Drug Discovery</i> , , 2016, , .		6
1108	Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells. <i>Journal of Immunology</i> , 2016, 197, 4829-4837.	0.4	30
1109	Flow Cytometry-based Assay for the Monitoring of NK Cell Functions. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	11
1111	Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 173, 950-957.	1.2	8
1112	Preserved Activity of CD20-Specific Chimeric Antigen Receptorâ€”Expressing T Cells in the Presence of Rituximab. <i>Cancer Immunology Research</i> , 2016, 4, 509-519.	1.6	27
1113	Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1105-1112.	1.4	5
1114	Ligand-targeted theranostic nanomedicines against cancer. <i>Journal of Controlled Release</i> , 2016, 240, 267-286.	4.8	154
1115	Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 710-720.	2.2	70
1116	Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2016, 101, 226-234.	1.7	31

#	ARTICLE	IF	CITATIONS
1117	Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus. <i>Paediatric Drugs</i> , 2016, 18, 181-195.	1.3	19
1118	Clinical Evaluation of ^{99m} Tc-Rituximab for Sentinel Lymph Node Mapping in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1214-1220.	2.8	18
1119	Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. <i>Seminars in Immunology</i> , 2016, 28, 309-316.	2.7	62
1120	SERS detection and targeted ablation of lymphoma cells using functionalized Ag nanoparticles. <i>Proceedings of SPIE</i> , 2016, , .	0.8	2
1121	War and peace: Factor VIII and the adaptive immune response. <i>Cellular Immunology</i> , 2016, 301, 2-7.	1.4	13
1122	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 821-826.	3.2	26
1123	A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2016, 9, 235-244.	1.0	9
1124	Mapping the effects of drugs on the immune system. <i>Nature Biotechnology</i> , 2016, 34, 47-54.	9.4	78
1125	Novel immunotherapies in lymphoid malignancies. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 25-40.	12.5	224
1126	Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 117-127.	0.7	49
1127	A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 275-290.	2.0	73
1128	CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. <i>Clinical Cancer Research</i> , 2017, 23, 193-203.	3.2	35
1129	A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. <i>Advances in Therapy</i> , 2017, 34, 324-356.	1.3	128
1130	A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. <i>Transplantation Reviews</i> , 2017, 31, 87-95.	1.2	53
1131	Changes in Cancer Treatment. <i>Nursing Clinics of North America</i> , 2017, 52, 65-81.	0.7	15
1132	Immunologic approaches for the treatment of multiple myeloma. <i>Cancer Treatment Reviews</i> , 2017, 55, 190-199.	3.4	46
1134	Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. <i>Drugs</i> , 2017, 77, 885-910.	4.9	18
1135	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. <i>Cancer Journal (Sudbury)</i> Tj ETQq1 1 0,784314 rgBT /Overl	1.0	8

#	ARTICLE	IF	CITATIONS
1136	Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results. , 2017, , 99-122.		0
1137	Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering. BioDrugs, 2017, 31, 151-166.	2.2	58
1138	Papillary thyroid carcinoma expressing CD20. Pathology International, 2017, 67, 350-354.	0.6	4
1139	Antibody-Based Cancer Therapy. International Review of Cell and Molecular Biology, 2017, 331, 289-383.	1.6	41
1140	Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method. International Immunopharmacology, 2017, 43, 23-32.	1.7	2
1141	Rituximab: 13 open questions after 20years of clinical use. Cancer Treatment Reviews, 2017, 53, 38-46.	3.4	48
1142	Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells. British Journal of Pharmacology, 2017, 174, 628-640.	2.7	22
1143	Humanized mouse model supports development, function, and tissue residency of human natural killer cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9626-E9634.	3.3	138
1144	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy, 2017, 34, 2232-2273.	1.3	407
1145	A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Scientific Reports, 2017, 7, 8951.	1.6	111
1146	Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review. International Immunology, 2017, 29, 319-325.	1.8	30
1147	Fixed Dosing of Monoclonal Antibodies in Oncology. Oncologist, 2017, 22, 1212-1221.	1.9	114
1148	Anti-SIRPÎ± antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10578-E10585.	3.3	223
1149	Multifunctional Nanomaterials for Cancer Theranostics. Frontiers in Nanobiomedical Research, 2017, , 227-283.	0.1	0
1150	Natural History, Pathogenesis, and Treatment of Evans Syndrome in Children. Journal of Pediatric Hematology/Oncology, 2017, 39, 413-419.	0.3	19
1151	Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. Clinical Pharmacology and Therapeutics, 2017, 101, 81-88.	2.3	37
1152	Update on the genetic architecture of rheumatoid arthritis. Nature Reviews Rheumatology, 2017, 13, 13-24.	3.5	102
1153	Targeting Oncoproteins for Molecular Cancer Therapy. , 2017, , 727-756.		0

#	ARTICLE	IF	CITATIONS
1154	Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. <i>Annals of Oncology</i> , 2017, 28, 457-467.	0.6	27
1155	Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 107-113.e1.	2.0	56
1156	Embedding real options in scenario planning: A new methodological approach. <i>Technological Forecasting and Social Change</i> , 2017, 124, 135-149.	6.2	29
1157	Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab. <i>Blood Reviews</i> , 2017, 31, 23-35.	2.8	15
1158	Helical coiled-coil peptide materials for biomedical applications. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1424.	3.3	45
1159	Sortase A-Generated Highly Potent Anti-CD20-CD20-MAE Conjugates for Efficient Elimination of B-Lineage Lymphomas. <i>Small</i> , 2017, 13, 1602267.	5.2	45
1160	B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia. <i>Journal of Autoimmunity</i> , 2017, 77, 89-95.	3.0	33
1161	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. <i>Journal of the Neurological Sciences</i> , 2017, 372, 92-96.	0.3	25
1162	Rituximab biosimilars open new horizons in immunotherapy. <i>ESMO Open</i> , 2017, 2, e000234.	2.0	3
1163	Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice. <i>Blood Advances</i> , 2017, 1, 1551-1564.	2.5	21
1164	A Canadian Perspective on the Subcutaneous Administration of Rituximab in Non-Hodgkin Lymphoma. <i>Current Oncology</i> , 2017, 24, 33-39.	0.9	13
1165	Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer. <i>Nanomaterials</i> , 2017, 7, 189.	1.9	302
1166	Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells. <i>Frontiers in Immunology</i> , 2017, 8, 455.	2.2	51
1167	Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors. <i>Frontiers in Immunology</i> , 2017, 8, 500.	2.2	69
1168	The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers. <i>Frontiers in Oncology</i> , 2017, 7, 93.	1.3	14
1169	Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. <i>BioMed Research International</i> , 2017, 2017, 1-18.	0.9	40
1170	Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients. <i>Journal of Immunology Research</i> , 2017, 2017, 1-24.	0.9	28
1171	The role of B cell antigen receptors in mantle cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 164.	6.9	17

#	ARTICLE	IF	CITATIONS
1172	Cancer Immunotherapy. , 2017, , 32-65.		1
1173	Precision Medicine: Where have we reached and where are we headed?. Sultan Qaboos University Medical Journal, 2017, 17, e255-258.	0.3	13
1174	Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines. Pathogens and Immunity, 2017, 2, 102.	1.4	11
1175	Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2018, 317, 1-4.	1.1	19
1176	Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4473-E4482.	3.3	96
1177	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction). Clinical Microbiology and Infection, 2018, 24, S2-S9.	2.8	52
1178	Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. Pediatric Nephrology, 2018, 33, 1013-1018.	0.9	19
1179	A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clinical and Translational Science, 2018, 11, 296-304.	1.5	22
1180	Recent advances in mass spectrometry-based approaches for proteomics and biologics: Great contribution for developing therapeutic antibodies. , 2018, 185, 147-154.		48
1181	Identification of MS4A3 as a reliable marker for early myeloid differentiation in human hematopoiesis. Biochemical and Biophysical Research Communications, 2018, 495, 2338-2343.	1.0	19
1182	Current Status of Immuno-Oncology in Hematologic Cancers. , 2018, , 641-655.		0
1183	Monoclonal Antibodies Targeting Hematological Malignancies. , 2018, , 79-116.		0
1184	A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice. Cancer Immunology, Immunotherapy, 2018, 67, 605-613.	2.0	4
1185	Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab. Journal of Neuroimmunology, 2018, 316, 107-111.	1.1	22
1186	Next-Generation Immunotherapy in Lymphoma: Checkpoint Blockade, Chimeric Antigen Receptor T Cells, and Beyond. , 2018, , 95-114.		0
1187	The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Annals of Clinical and Translational Neurology, 2018, 5, 710-716.	1.7	34
1188	Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts. Neoplasia, 2018, 20, 443-455.	2.3	17
1189	Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Reviews, 2018, 32, 387-399.	2.8	54

#	ARTICLE	IF	CITATIONS
1190	The tumour microenvironment links complement system dysregulation and hypoxic signalling. British Journal of Radiology, 2019, 92, 20180069.	1.0	10
1191	Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study). Pathology and Oncology Research, 2018, 24, 199-205.	0.9	5
1192	Incidence of Hepatitis B Viral Reactivation After Kidney Transplantation With Low-Dose Rituximab Administration. Transplantation, 2018, 102, 140-145.	0.5	17
1193	Tolerance and Autoimmunity. , 2018, , 285-294.		0
1194	Complement in cancer: untangling an intricate relationship. Nature Reviews Immunology, 2018, 18, 5-18.	10.6	279
1195	Hypersensitivity Reactions to Monoclonal Antibodies. , 2018, , 211-221.		0
1196	Progressive Multiple Sclerosis. , 2018, , .		1
1197	Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. Autoimmunity Reviews, 2018, 17, 115-124.	2.5	48
1198	Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies <i>In Vivo</i>. Clinical Cancer Research, 2018, 24, 1114-1123.	3.2	25
1199	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
1200	Novel agents for relapsed and refractory follicular lymphoma. Best Practice and Research in Clinical Haematology, 2018, 31, 41-48.	0.7	19
1201	A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e51-e60.	0.2	6
1202	Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Multiple Sclerosis Journal, 2018, 24, 1224-1233.	1.4	86
1203	Targeting tumor cells with antibodies enhances anti-tumor immunity. Biophysics Reports, 2018, 4, 243-253.	0.2	17
1204	Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e498.	3.1	81
1205	The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nation-wide cancer registry-based study from Taiwan. Cancer Medicine, 2018, 7, 5775-5788.	1.3	27
1206	Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2018, 8, 351.	1.3	71
1207	Lenalidomide and R-CHOP in follicular lymphoma: where do we go from here?. Lancet Haematology,the, 2018, 5, e381-e382.	2.2	0

#	ARTICLE	IF	CITATIONS
1208	Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 555-569.	1.2	6
1209	Adult leukemia survival trends in the United States by subtype: A population-based registry study of 370,994 patients diagnosed during 1995-2009. <i>Cancer</i> , 2018, 124, 3856-3867.	2.0	33
1210	Cancers of the eye. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 677-690.	2.7	55
1211	Diagnosis, Treatment, and Outcomes of Antibody-Mediated Rejection in Kidney Transplantation. , 2018, , .		0
1212	Multidisciplinary Care of the Pediatric Cancer Patient. , 2018, , 101-113.		0
1213	An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 508-518.e14.	0.2	11
1214	Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment. <i>Clinical Journal of Oncology Nursing</i> , 2018, 22, 407-414.	0.3	5
1215	Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. <i>Frontiers in Immunology</i> , 2017, 8, 1936.	2.2	39
1216	Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 163.	1.3	238
1217	Combination of ¹⁷⁷ Lu-tilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2018, 101, 522-531.	1.1	18
1218	Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 45.	1.3	5
1219	Monitoring B-cell repopulation after depletion therapy in neurologic patients. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e463.	3.1	65
1220	Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis. <i>Internal Medicine</i> , 2018, 57, 2247-2250.	0.3	7
1221	First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. <i>Oncotarget</i> , 2018, 9, 13023-13035.	0.8	70
1222	Lymphoma in India™ at the Dawn of Targeted Therapies. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 385-386.	0.3	0
1223	Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. <i>Cancer Immunology Research</i> , 2018, 6, 1150-1160.	1.6	57
1224	Novel potential inhibitors of complement system and their roles in complement regulation and beyond. <i>Molecular Immunology</i> , 2018, 102, 73-83.	1.0	49
1225	Cancer immunotherapy: broadening the scope of targetable tumours. <i>Open Biology</i> , 2018, 8, .	1.5	162

#	ARTICLE	IF	CITATIONS
1226	Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab. <i>Nature Communications</i> , 2019, 10, 3705.	5.8	38
1227	Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia. <i>Future Oncology</i> , 2019, 15, 2687-2697.	1.1	0
1228	Invasive fungal infections in the immunocompromised host: Mechanistic insights in an era of changing immunotherapeutics. <i>Medical Mycology</i> , 2019, 57, S307-S317.	0.3	23
1229	Targeted treatment of CD22-positive non-Hodgkin's lymphoma with sialic acid-modified chitosan-PLGA hybrid nanoparticles. <i>Journal of Nanoparticle Research</i> , 2019, 21, 1.	0.8	4
1230	Attacking Latent HIV with convertible CAR-T Cells, a Highly Adaptable Killing Platform. <i>Cell</i> , 2019, 179, 880-894.e10.	13.5	95
1231	Demystifying Cancer Immunotherapy for Lay Audiences. <i>Frontiers in Immunology</i> , 2019, 10, 2488.	2.2	4
1232	Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients. <i>PLoS ONE</i> , 2019, 14, e0224203.	1.1	10
1233	Fc Mediated Activity of Antibodies. <i>Current Topics in Microbiology and Immunology</i> , 2019, , .	0.7	4
1234	Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma. <i>Molecular Medicine Reports</i> , 2019, 20, 3679-3690.	1.1	2
1236	Rituximab – A novel therapy for severe ITP in pregnancy: A case report. <i>Obstetric Medicine</i> , 2019, 12, 196-198.	0.5	4
1237	SERS-based dynamic monitoring of minimal residual disease markers with high sensitivity for clinical applications. <i>Nanoscale</i> , 2019, 11, 2460-2467.	2.8	17
1238	Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?. <i>Haematologica</i> , 2019, 104, 1124-1135.	1.7	58
1239	Principles of Immunotherapy. , 2019, , 295-304.		0
1240	Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies. <i>International Journal of Biological Macromolecules</i> , 2019, 135, 907-918.	3.6	62
1241	CD81 is a novel immunotherapeutic target for B cell lymphoma. <i>Journal of Experimental Medicine</i> , 2019, 216, 1497-1508.	4.2	31
1242	Racial disparities, cancer and response to oxidative stress. <i>Advances in Cancer Research</i> , 2019, 144, 343-383.	1.9	10
1243	CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 829-843.	1.4	34
1244	Posterior Uveitis. <i>Essentials in Ophthalmology</i> , 2019, , .	0.0	0

#	ARTICLE	IF	CITATIONS
1245	Rituximab dosing in hematological malignancies: an old question, revisited. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 661-666.	1.1	2
1246	Monoclonal Antibodies in Cancer. , 2019, , 489-519.		0
1247	Physicochemical and Biological Characterization of RTX83, a New Rituximab Biosimilar. <i>BioDrugs</i> , 2019, 33, 307-319.	2.2	20
1249	Noninfectious Uveitis: Immunomodulatory Agents and Biologicals. <i>Essentials in Ophthalmology</i> , 2019, , 175-207.	0.0	0
1250	Role of FcγRs in Antibody-Based Cancer Therapy. <i>Current Topics in Microbiology and Immunology</i> , 2019, 423, 13-34.	0.7	13
1251	Drug repositioning in pulmonary arterial hypertension: challenges and opportunities. <i>Pulmonary Circulation</i> , 2019, 9, 1-18.	0.8	20
1252	Minimal Change Disease, <i>Pediatric</i> . , 2019, , 115-135.		0
1253	20 years of rituximab treatment: what have we learnt?. <i>Future Oncology</i> , 2019, 15, 4119-4121.	1.1	2
1254	Concurrent treatment with rituximab and plasma exchange for severe refractory granulomatosis with polyangiitis. <i>Medicine (United States)</i> , 2019, 98, e18139.	0.4	3
1256	Monoclonal Antibodies: Past, Present and Future. <i>Handbook of Experimental Pharmacology</i> , 2019, 260, 81-141.	0.9	41
1257	Clinical Features of Rituximab-associated Gastrointestinal Toxicities. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 539-545.	0.6	19
1258	Preclinical Studies of ADC Therapy for Solid Tumors. , 2019, , 125-154.		0
1260	Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients. <i>Journal of Dermatology</i> , 2019, 46, 124-130.	0.6	17
1261	Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study. <i>Journal of Neurology</i> , 2019, 266, 642-650.	1.8	25
1262	Position of Scientific Oncological Societies Towards Biosimilar Antibodies. <i>Breast Care</i> , 2019, 14, 5-8.	0.8	3
1263	Cancer Immunotherapy: The Dawn of Antibody Cocktails. <i>Methods in Molecular Biology</i> , 2019, 1904, 11-51.	0.4	25
1264	RNA sequencing for research and diagnostics in clinical oncology. <i>Seminars in Cancer Biology</i> , 2020, 60, 311-323.	4.3	56
1265	Concepts for agonistic targeting of CD40 in immuno-oncology. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 377-387.	1.4	42

#	ARTICLE	IF	CITATIONS
1266	Development of therapeutic antibodies for the treatment of diseases. <i>Journal of Biomedical Science</i> , 2020, 27, 1.	2.6	1,277
1267	Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. <i>Nature Reviews Rheumatology</i> , 2020, 16, 32-52.	3.5	68
1268	Flow Cytometric Analyses of Lymphocyte Markers in Immune Oncology: A Comprehensive Guidance for Validation Practice According to Laws and Standards. <i>Frontiers in Immunology</i> , 2020, 11, 2169.	2.2	14
1269	Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product. <i>Biologics</i> , 2020, 68, 79-91.	0.5	14
1270	Colorectal Cancer Immunotherapy: Options and Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 1624.	2.2	207
1271	Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. <i>Urologic Clinics of North America</i> , 2020, 47, 487-510.	0.8	10
1272	Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy. <i>European Thyroid Journal</i> , 2020, 9, 31-39.	1.2	5
1273	False-positive semiquantitative immunochromatography assays for procalcitonin in three patients with rheumatoid arthritis—A case series. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 1704-1707.	0.2	4
1274	Monoclonal Antibodies in Cancer Therapy. <i>Antibodies</i> , 2020, 9, 34.	1.2	325
1275	Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma. <i>Cell Death Discovery</i> , 2020, 6, 127.	2.0	10
1276	CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9531.	1.8	16
1277	Complement Activation in the Treatment of B-Cell Malignancies. <i>Antibodies</i> , 2020, 9, 68.	1.2	4
1278	Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy. <i>Annals of Hematology</i> , 2020, 99, 2141-2148.	0.8	9
1279	Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome. <i>Pediatric Nephrology</i> , 2020, 35, 2003-2008.	0.9	11
1281	Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications. <i>International Journal of Cancer</i> , 2020, 147, 1979-1986.	2.3	6
1282	CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. <i>Blood</i> , 2020, 136, 2416-2427.	0.6	77
1283	IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia. <i>Scientific Reports</i> , 2020, 10, 3051.	1.6	12
1284	Antigen specific B cells in myasthenia gravis patients. <i>Immunological Medicine</i> , 2020, 43, 65-71.	1.4	5

#	ARTICLE	IF	CITATIONS
1285	Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. <i>Science</i> , 2020, 367, 1224-1230.	6.0	113
1286	An extension of the RITUXÂ€RAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibodyâ€mediated rejection after renal transplantation. <i>Transplant International</i> , 2020, 33, 786-795.	0.8	18
1287	Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 563-571.	0.2	10
1288	Pluripotent stem cellâ€derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. <i>Blood</i> , 2020, 135, 399-410.	0.6	166
1290	Stem Cell as Vehicles of Antibody in Treatment of Lymphoma: a Novel and Potential Targeted Therapy. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 829-841.	1.7	3
1291	Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 751-754.	0.2	1
1292	Role of immunoglobulin and antibodies in disease management. <i>International Journal of Biological Macromolecules</i> , 2021, 169, 28-38.	3.6	41
1293	Surveillance of the current situation regarding influenza vaccination according to medical oncologists in Japan. <i>Cancer Science</i> , 2021, 112, 433-443.	1.7	1
1294	Incidence, Clinical Features, and Outcomes of Lateâ€Onset Neutropenia From Rituximab for Autoimmune Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 347-354.	2.9	25
1295	Anti-CD20 treatment for B-cell malignancies: current status and future directions. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 161-181.	1.4	24
1296	Gene Therapy and Gene Editing for Cancer Therapeutics. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 116-204.	0.1	0
1297	Hydrogen deuterium exchange mass spectrometry identifies the dominant paratope in CD20 antigen binding to the NCD1.2 monoclonal antibody. <i>Biochemical Journal</i> , 2021, 478, 99-120.	1.7	3
1298	Therapeutic Approaches to Employ Monoclonal Antibody for Cancer Treatment. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 42-88.	0.1	0
1299	Editorial: Complement and Immunotherapeutics. <i>Frontiers in Immunology</i> , 2021, 12, 663459.	2.2	0
1300	On the Shoulders of a Giant: Contributions of Thomas Grogan, MD to Hematopathology. <i>Hemato</i> , 2021, 2, 103-115.	0.2	0
1301	Monoclonal antibody-based cancer therapies. <i>Chinese Journal of Chemical Engineering</i> , 2021, 30, 301-307.	1.7	7
1302	Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells. <i>Gene Therapy</i> , 2021, 28, 602-612.	2.3	9
1303	Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. <i>Cells</i> , 2021, 10, 670.	1.8	20

#	ARTICLE	IF	CITATIONS
1304	Complement in Tumourigenesis and the Response to Cancer Therapy. <i>Cancers</i> , 2021, 13, 1209.	1.7	18
1305	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 209-221.	2.5	88
1306	A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. <i>Journal of Medical Toxicology</i> , 2021, 17, 411-424.	0.8	54
1307	Novel therapies targeting cutaneous T cell lymphomas and their microenvironment. <i>Seminars in Hematology</i> , 2021, 58, 103-113.	1.8	4
1308	The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 654877.	2.2	19
1309	Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors. <i>Current Chemical Biology</i> , 2021, 15, 19-49.	0.2	2
1310	Construction and Characterization of 1F5 Chimeric Anti-CD20 Monoclonal Antibodies: an Efficient Splicing by Overlap Extension-polymerase Chain Reaction Technique. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 0, , .	0.3	0
1311	Antibody Therapies for Large B-Cell Lymphoma. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 153-174.	3.0	0
1312	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 678-689.	5.1	83
1313	A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial. <i>BMC Cancer</i> , 2021, 21, 749.	1.1	5
1314	Biologic Therapy and Severe Asthma in Children. <i>Biomedicines</i> , 2021, 9, 760.	1.4	14
1315	Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome. <i>Pediatric Nephrology</i> , 2022, 37, 357-365.	0.9	11
1316	Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration. <i>Cells</i> , 2021, 10, 1471.	1.8	9
1317	COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma. <i>HemaSphere</i> , 2021, 5, e603.	1.2	35
1318	CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. <i>Lung Cancer</i> , 2021, 157, 48-59.	0.9	16
1319	Immunotherapies in Non-Hodgkin's Lymphoma. <i>Cancers</i> , 2021, 13, 3625.	1.7	5
1320	Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease. <i>BMC Nephrology</i> , 2021, 22, 242.	0.8	2
1321	Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation. <i>Frontiers in Medicine</i> , 2021, 8, 707104.	1.2	11

#	ARTICLE	IF	CITATIONS
1322	First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2021, 23, 211.	1.6	12
1323	Targeted immunotherapies to consider for B Cell non-hodgkin lymphoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 317-332.	0.4	0
1324	Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, .	0.9	1
1325	The tetraspan MS4A family in homeostasis, immunity, and disease. <i>Trends in Immunology</i> , 2021, 42, 764-781.	2.9	33
1326	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. <i>Cancers</i> , 2021, 13, 4797.	1.7	12
1327	Prognostic Indicators of Survival in Sinonasal Diffuse Large Cell Lymphoma: A National Cancer Database Analysis. <i>Laryngoscope</i> , 2022, 132, 1515-1522.	1.1	5
1328	OUP accepted manuscript. <i>American Journal of Clinical Pathology</i> , 2021, , .	0.4	0
1329	Neurological Complications. , 2021, , 593-622.		0
1330	The Indolent B-Cell Lymphomas. , 2006, 131, 89-120.		4
1331	Therapy of diffuse aggressive lymphomas. , 1999, 99, 47-73.		1
1332	Monoclonal Antibodies in Cancer Therapy. , 2007, , 453-484.		1
1333	The Use of Antibodies in Diagnosis and Therapy of Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2003, 534, 309-325.	0.8	3
1334	Orbital and Ocular Adnexal Lymphoma. , 2015, , 145-153.		2
1335	Immunocytokines for Cancer Immunotherapy. , 2004, , 341-358.		7
1336	Therapeutic Human Monoclonal Antibodies in Inflammatory Diseases. <i>Methods in Molecular Biology</i> , 2014, 1060, 37-59.	0.4	49
1337	Polyclonal and Monoclonal Antibodies in Clinic. <i>Methods in Molecular Biology</i> , 2014, 1060, 79-110.	0.4	30
1338	Engineered Antibody for Treating Lymphoma. <i>Recent Results in Cancer Research</i> , 2002, 159, 104-112.	1.8	12
1339	Treatment of Post-Transplant Lymphomas with Anti-B-Cell Monoclonal Antibodies. <i>Recent Results in Cancer Research</i> , 2002, 159, 113-122.	1.8	23

#	ARTICLE	IF	CITATIONS
1340	Infusional CDE with Rituximab for the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma: Preliminary Results of a Phase I/II Study. <i>Recent Results in Cancer Research</i> , 2002, 159, 149-153.	1.8	36
1341	CpG DNA in Cancer Immunotherapy. <i>Current Topics in Microbiology and Immunology</i> , 2000, 247, 157-170.	0.7	17
1342	Monoclonal antibody therapy. , 2009, , 303-406.		4
1343	Regulatory process for approval of biologicals for cancer therapy. , 2009, , 613-629.		1
1344	Monoclonal antibody therapy. , 2003, , 329-390.		3
1345	Non-Hodgkin's Lymphoma. , 2008, , 2371-2404.		3
1346	Malignant Diseases in Human Immunodeficiency Virus Infection. , 2010, , 1765-1779.		1
1347	Molecular Diagnosis of the Lymphomas by Gene Expression Profiling. , 2006, , 110-126.		2
1348	Chemotherapy for Primary Central Nervous System Lymphoma. , 2006, , 395-406.		1
1349	Follicular Lymphoma. , 2006, , 348-373.		1
1350	Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. <i>The Hematology Journal</i> , 2001, 2, 300-306.	2.0	69
1351	Tumor necrosis factor α release is a major biological event associated with rituximab treatment. <i>The Hematology Journal</i> , 2001, 2, 378-384.	2.0	88
1352	CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia. <i>Bioscience Reports</i> , 2020, 40, .	1.1	7
1353	Detection of bcl-2/IgH rearrangements by quantitative-competitive PCR and capillary electrophoresis. <i>Molecular Diagnosis and Therapy</i> , 2001, 6, 161-8.	1.3	4
1354	Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis. <i>Leukemia and Lymphoma</i> , 2001, 42, 1329-1337.	0.6	32
1355	Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. <i>Current Opinion in Oncology</i> , 1999, 11, 96.	1.1	40
1356	Rituximab (IDEC-C2B8): Validation of a Sensitive Enzyme-Linked Immunoassay Applied to a Clinical Pharmacokinetic Study. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 295-301.	1.0	60
1357	TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH THE ANTI-CD20 MONOCLONAL ANTIBODY RITUXIMAB ALONE IN AN ADULT AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 2000, 69, 430-432.	0.5	57

#	ARTICLE	IF	CITATIONS
1358	TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE WITH RITUXIMAB. Transplantation, 2002, 73, 100-104.	0.5	113
1359	Hodgkin's disease and non-Hodgkin's lymphoma. Current Opinion in Hematology, 1999, 6, 205.	1.2	7
1360	Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches. Current Opinion in Hematology, 1999, 6, 222.	1.2	6
1361	Chronic lymphocytic leukemia. Current Opinion in Hematology, 1999, 6, 253.	1.2	43
1362	Stem cell transplantation for indolent lymphoma. Current Opinion in Hematology, 1999, 6, 388.	1.2	2
1364	Minimal change disease with maximum immunosuppression: successful treatment of steroid-dependent minimal change disease with rituximab. BMJ Case Reports, 2018, 2018, bcr-2017-223407.	0.2	2
1365	Abstract 3193: Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51. Cancer Research, 2017, 77, 3193-3193.	0.4	7
1366	Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood, 2002, 100, 2260-2262.	0.6	9
1367	Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood, 2000, 96, 3544-3552.	0.6	6
1368	The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. Journal of Leukocyte Biology, 2002, 68, 455-463.	1.5	73
1369	The Discovery of Rituxan. , 2006, , 565-584.		1
1370	Neuromyelitis Optica Spectrum Disorders. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 864-896.	0.4	22
1371	Rituximab efficiently depletes B cells in lung tumors and normal lung tissue. F1000Research, 2016, 5, 38.	0.8	15
1372	The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine. PLoS ONE, 2016, 11, e0148366.	1.1	33
1373	Primary B-Cell Mucosa-Associated Lymphoid Tissue Lymphoma of the Hard Palate and Parotid Gland: Report of One Case and Review of the Literature. Journal of Clinical Medicine Research, 2016, 8, 824-830.	0.6	7
1374	The Role of Rituximab in Lymphomas. Revista Brasileira De Hematologia E Hemoterapia, 2002, 24, .	0.7	1
1375	The Rationale for Performing Autologous Peripheral Blood Stem Cell Transplants in Community Cancer Centers. Oncologist, 1998, 3, 346-353.	1.9	5
1376	Conflict of Interest in Medical Research, Education, and Practice. , 2009, , .		163

#	ARTICLE	IF	CITATIONS
1377	A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma. Sultan Qaboos University Medical Journal, 2015, 15, e317-321.	0.3	13
1378	A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77. Oncotarget, 2018, 9, 3631-3640.	0.8	11
1380	Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells. Oncotarget, 2016, 7, 12806-12822.	0.8	10
1381	Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab. Oncotarget, 2016, 7, 28262-28272.	0.8	13
1382	A case of platelet transfusion refractoriness due to anti-CD36 with a successful treatment outcome. Immunohematology, 2019, 35, 139-144.	0.2	7
1383	Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era. Current Medicinal Chemistry, 2019, 26, 1002-1018.	1.2	11
1384	Cytotoxic Activity of CD48 Monoclonal Antibodies Against Human Lymphoma Cells. Open Biotechnology Journal, 2008, 2, 219-223.	0.6	1
1385	Reactive Oxygen Species, Cancer and Anti-Cancer Therapies. Current Chemical Biology, 2009, 3, 22-46.	0.2	53
1386	Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy. World Journal of Gastroenterology, 2005, 11, 4443.	1.4	4
1387	Individualized management of follicular lymphoma. Chinese Clinical Oncology, 2015, 4, 7.	0.4	7
1388	Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab. Chinese Clinical Oncology, 2016, 5, 5.	0.4	6
1389	Pneumonitis After Precision Oncology Therapies: A Concise Review. Journal of Immunotherapy and Precision Oncology, 2018, 1, 26-37.	0.6	5
1390	Clinical Prognostic Factors and Treatment Outcome of Aggressive Non-Hodgkin's Lymphoma in Elderly Patients. Cancer Research and Treatment, 2001, 33, 324-328.	1.3	2
1391	Rituximab levels are associated with the B cell homeostasis but not with the clinical response in patients with rheumatoid arthritis. European Journal of Rheumatology, 2019, 6, 78-81.	1.3	3
1392	Structure guided homology model based design and engineering of mouse antibodies for humanization. Bioinformation, 2014, 10, 180-186.	0.2	7
1393	Tumor-associated antigens and development of immunotherapeutics strategies. Biopolymers and Cell, 2005, 21, 220-229.	0.1	1
1394	Emerging Therapies for Multiple Sclerosis. International Journal of MS Care, 2010, 12, 17-22.	0.4	1
1395	Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biology and Medicine, 2014, 11, 20-33.	1.4	109

#	ARTICLE	IF	CITATIONS
1396	Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature. <i>Drugs in Context</i> , 2020, 9, 1-12.	1.0	6
1397	Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. <i>Molecular Biology Reports</i> , 2021, 48, 8075-8095.	1.0	40
1398	New Directions in Immunopharmacotherapy. , 2000, , 315-346.		0
1399	T-Bodies as Antiviral Agents. <i>Current Topics in Microbiology and Immunology</i> , 2001, 260, 271-300.	0.7	6
1400	Stellenwert molekularbiologischer Verfahren in der klinischen HÄmatologie und Onkologie. , 2001, , 345-361.		0
1401	Non-Hodgkinâ€™s Lymphoma. , 2001, , 310-322.		0
1402	Immunostimulatory DNA sequences and cancer therapy. , 2001, , 107-116.		0
1403	HAL-01. , 2001, , 99-100.		0
1404	Gene Therapy for Infectious Diseases. , 2001, , 127-146.		0
1405	The Spleen in Lymphoproliferative Disease. , 2002, , 223-250.		0
1406	Innovations in Cancer Therapeutics. , 2002, , 93-116.		0
1408	The Rise of Antibodies as Therapeutics. <i>Lung Biology in Health and Disease</i> , 2002, , 427-469.	0.1	0
1409	Human tumor antigens recognized by antibodies (SEREX). , 2003, , 161-171.		0
1410	Non-Hodgkinâ€™s Lymphoma. , 2003, , 295-318.		0
1411	Human tumor antigens recognized by antibodies (SEREX). , 2003, , 179-189.		0
1412	EBV Lymphoproliferative Disease After Transplantation. , 2004, , 259-270.		0
1413	Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia. , 2004, , 269-298.		0
1414	Maligne Lymphome. , 2004, , 1711-1774.		0

#	ARTICLE	IF	CITATIONS
1415	Tumorimmunologie. , 2004, , 355-380.		0
1417	Mantelzell-Lymphom (zentrozytisches Lymphom). , 2006, , 2953-2986.		0
1418	Primary Extranodal Non-Hodgkin's Lymphomas. , 2006, , 325-347.		17
1419	Epstein-Barr Virus and HIV. Infectious Disease and Therapy, 2006, , 175-186.	0.0	1
1420	A non-Hodgkin lymphoma patient with reactivation of HBV during chemotherapy and emergence of a YMDD-motif mutant on lamivudine, eventually controlled by adfovil dipovoxil. Acta Hepatologica Japonica, 2007, 48, 309-316.	0.0	0
1421	Development of a New Fully Human Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies.. Blood, 2007, 110, 2349-2349.	0.6	1
1422	Pharmacogenetic Issues in Biopharmaceutical Drug Development. , 2008, , 99-120.		0
1424	Chapter 2. Chemical Engineering of Therapeutic Antibodies. , 2008, , 11-24.		0
1425	EBV Lymphoproliferative Disease after Transplantation. , 2008, , 449-465.		0
1426	Efficacy and Adverse Effects of Rituximab Combined with a TCOP Regimen in Patients with Untreated Diffuse Large B-cell Lymphoma and Follicular Lymphoma. The Showa University Journal of Medical Sciences, 2009, 21, 215-225.	0.1	0
1427	TRANSPLANT MEDICINE. , 2009, , 1269-1294.		0
1429	Biologic Therapies for Multiple Myeloma and Plasma Cell Disorders. , 2009, , .		0
1430	Biologic Therapies for Chronic Lymphocytic Leukemia. , 2009, , .		0
1431	Biologic Therapies For Non-hodgkin Lymphoma And Hodgkin Disease. , 2009, , .		0
1433	Targeted Therapy in Hematologic Malignancies. , 2011, , 293-323.		0
1434	Targeted Therapeutics in Cancer Treatment. , 2011, , 403-461.		0
1436	Clinical Applications of Systems Biology Approaches. , 2011, , 409-428.		0
1437	A case of malignant lymphoma arising in the margin of the tongue. Nihon Koku Geka Gakkai Zasshi, 2011, 57, 269-273.	0.0	2

#	ARTICLE	IF	CITATIONS
1438	Lymphoproliferation and Lymphoma in Sjögren's Syndrome. , 2011, , 345-355.		0
1440	Use of rHuG-CSF in New Chemotherapy Strategies. , 2012, , 225-247.		0
1441	Repeated administration of rituximab for refractory nephrotic syndrome in children. Japanese Journal of Pediatric Nephrology, 2012, 25, 27-33.	0.0	0
1442	Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 73-92.	0.1	0
1443	Monoclonal Antibodies in Cancer. , 2013, , 337-359.		1
1444	Idiotypic Vaccination: Still a Unique form of Cancer Immunotherapy for Follicular Lymphoma after 20 Years. Advances in Cancer: Research & Treatment, 2013, , 1-13.	0.0	0
1446	Lymphomes : principes thérapeutiques et imagerie post-thérapeutique. , 2014, , 265-298.		0
1447	Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases. World Journal of Hematology, 2014, 3, 29.	0.1	0
1448	Non-Hodgkin-Lymphome niedriger Malignität. , 1998, , 257-332.		0
1449	Cancer Immunotherapy. , 1999, , 170-204.		0
1450	Passenger lymphocyte syndrome: a forgotten cause of postliver transplant jaundice and anemia. Experimental and Clinical Transplantation, 2015, 13, 200-2.	0.2	4
1451	Molecular Targeted Anticancer Drugs. , 2016, , 175-238.		0
1452	Trials of Novel Therapies Specifically for Progressive MS. , 2018, , 233-252.		0
1453	Minimal Change Disease, Pediatric. , 2018, , 1-20.		0
1455	Resistance to Monoclonal Antibody Therapeutics in Lymphoma. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 27-55.	0.1	0
1456	Swords to Ploughshares and Back: The Continuing Threat of Immunomodulatory Research and Development. , 2019, , 195-223.		0
1457	Molecular and clinical progress in follicular lymphoma lacking the t(14;18) translocation (Review). International Journal of Oncology, 2020, 56, 7-17.	1.4	3
1458	Antibody Therapy in Follicular Lymphoma. , 2020, , 189-206.		0

#	ARTICLE	IF	CITATIONS
1459	Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. , 2020, , 159-212.		0
1460	Modern pharmacological approaches to primary treatment nephrotic syndrome. Nephrology (Saint-Petersburg), 2020, 24, 9-20.	0.1	0
1461	Retrospective Study of Infusion Reactions during Re-administration of Rituximab. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2020, 46, 7-13.	0.0	0
1462	Comparison of one-bag and multibag desensitization protocols for the prevention of rituximab hypersensitivity. Allergy Asthma & Respiratory Disease, 2020, 8, 135.	0.3	3
1463	Neurological Toxicities of Immunotherapy. , 2020, , 223-242.		0
1464	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
1465	Chapter 33: Therapeutic Applications of Radioactive Agents. , 2020, , .		0
1468	Monoclonal Antibodies in the Treatment of Non-Hodgkinâ€™s Lymphoma. , 2006, 131, 221-250.		2
1469	Monoclonal Antibodies in Lymphomas. , 2007, , 511-536.		0
1471	An updated view of the pathogenesis of steroid-sensitive nephrotic syndrome. Pediatric Nephrology, 2022, 37, 1957-1965.	0.9	13
1472	The Contribution of Liver Sinusoidal Endothelial Cells to Clearance of Therapeutic Antibody. Frontiers in Physiology, 2021, 12, 753833.	1.3	8
1473	Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas. Cancers, 2022, 14, 626.	1.7	11
1474	Targeted Therapy in Leukaemia, Lymphoma and Myeloma. Journal of Personalized Medicine, 2022, 12, 74.	1.1	1
1475	The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma. Leukemia and Lymphoma, 2022, , 1-10.	0.6	2
1476	Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer. JAMA Oncology, 2022, 8, 537.	3.4	11
1477	A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Leukemia and Lymphoma, 2022, 63, 1750-1753.	0.6	1
1478	New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?. Frontiers in Immunology, 2022, 13, 805697.	2.2	15
1480	Significance of immunotherapy for human bacterial diseases and antibacterial drug discovery. , 2022, , 129-161.		3

#	ARTICLE	IF	CITATIONS
1481	Prognostic factors of severe pneumonia in patients treated with rituximab in the intensive care unit. <i>Journal of International Medical Research</i> , 2022, 50, 030006052110632.	0.4	1
1482	High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand. <i>Cancers</i> , 2022, 14, 1325.	1.7	14
1483	Targeted Liposomes: A Nonviral Gene Delivery System for Cancer Therapy. <i>Pharmaceutics</i> , 2022, 14, 821.	2.0	27
1484	Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile. <i>Life</i> , 2022, 12, 48.	1.1	49
1485	Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 823174.	1.6	10
1490	Therapeutic strategies for aggressive lymphomas: The trials of the DSHNHL. <i>Annals of Hematology</i> , 2001, 80, B77-B83.	0.8	7
1491	The pharmacokinetics of ^{125}I -rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab. <i>Human Antibodies</i> , 2011, 20, 37-40.	0.6	0
1492	Development of Cancer Immunotherapies. <i>Cancer Treatment and Research</i> , 2022, 183, 1-48.	0.2	4
1493	Liposomes in the Targeted Gene Therapy of Cancer: A Critical Review. <i>Current Drug Delivery</i> , 2023, 20, 350-370.	0.8	7
1494	Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review. <i>European Journal of Haematology</i> , 2022, 109, 166-181.	1.1	3
1495	Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	0
1496	Rituximab and future biological therapies. , 2013, , 333-341.e3.		1
1498	The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics. <i>Leukemia Research Reports</i> , 2022, 18, 100335.	0.2	2
1499	Cyclophosphamide for Treatment of Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2022, 44, 1058-1070.	1.1	1
1501	Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. <i>Future Oncology</i> , 2022, 18, 2943-2966.	1.1	12
1502	Late-onset toxicities of monoclonal antibodies in cancer patients. <i>Immunotherapy</i> , 2022, 14, 1067-1083.	1.0	3
1503	Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses. <i>IScience</i> , 2022, 25, 105067.	1.9	2
1504	Detection of bcl-2/IgH Rearrangements by Quantitative-competitive PCR and Capillary Electrophoresis. <i>Molecular Diagnosis and Therapy</i> , 2001, 6, 161-168.	1.3	0

#	ARTICLE	IF	CITATIONS
1505	Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences. Indian Journal of Medical Research, 2022, 155, 335.	0.4	7
1506	Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects. Nephrology Dialysis Transplantation, 2023, 38, 939-949.	0.4	10
1507	Drug allergy: A 2022 practice parameter update. Journal of Allergy and Clinical Immunology, 2022, 150, 1333-1393.	1.5	131
1508	The global landscape of approved antibody therapies. Antibody Therapeutics, 2022, 5, 233-257.	1.2	19
1509	Off-Label Uses of Rituximab in Dermatology. Current Dermatology Reports, 0, , .	1.1	2
1511	Utilization of real-world data in assessing treatment effectiveness for diffuse large B-cell lymphoma. American Journal of Hematology, 2023, 98, 180-192.	2.0	3
1512	MYC and therapy resistance in cancer: risks and opportunities. Molecular Oncology, 2022, 16, 3828-3854.	2.1	20
1514	Evolving therapeutic proteins to precisely kill cancer cells. Journal of Controlled Release, 2022, 351, 779-804.	4.8	2
1515	Search for Risk Factors Influencing the Occurrence of Infusion Reaction after Initial Treatment with Obinutuzumab. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2021, 47, 631-638.	0.0	2
1516	Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting. Clinical and Translational Science, 2023, 16, 305-312.	1.5	2
1517	Overview of the Risk of Infection Associated with Biologic and Target Therapies. , 2022, , 3-15.		0
1518	A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy. JCI Insight, 2022, 7, .	2.3	5
1519	Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options. OncoTargets and Therapy, 0, Volume 15, 1481-1501.	1.0	11
1520	Advancements in Cancer Immunotherapies. Vaccines, 2023, 11, 59.	2.1	8
1521	Introduction on Cancer Immunotherapy. , 2023, , 1-27.		0
1522	Emerging Trends in Monoclonal Antibody Therapies Targeting Cancer. , 2023, , 1-48.		0
1523	Radiolabeled Antibodies for Imaging and Targeted Therapy. , 2023, , 533-575.		0
1524	Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions. Leukemia Research, 2023, 129, 107072.	0.4	1

#	ARTICLE	IF	CITATIONS
1525	A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic,		

